

## CURRICULUM VITAE

### Personal Information:

  
Name: George Yancey Gillespie, III, Ph.D.  
Home Address: 5704 12<sup>th</sup> Avenue South  
Birmingham, AL 35222  
Office Address: 668B Volker Hall  
1670 University Boulevard  
Birmingham, AL 35294-0019  
Telephone: Home: (205) 592-3724  
Laboratory: (205) 934-7227  
Office: (205) 975-0438  
Fax: (205) 975-7667  
Cell: (205) 862-0557  
e-mail: gygillespie@uabmc.edu  
Date and Place of Birth: October 29, 1943 Greenwood, MS  
Marital Status: Married (wife, Lady Jane C.)

12/19/2017

### Education - Postgraduate Training:

University of Mississippi, 1965, B.A., Biology and Chemistry  
University of Mississippi, 1968, M.S., Cytogenetics  
*Population dynamics in single cell clones of the Ehrlich ascites carcinoma.* Master of Science Thesis. The University of Mississippi, University, MS, 20 pp., 1968.  
University of Mississippi, 1971, Ph.D., Immunology and Immunochemistry  
*Mediation and suppression of allograft immunity in vitro: A model for immunologic enhancement.* Doctor of Philosophy Dissertation. The University of Mississippi, University, MS, 110 pp., 1971.  
University of Kansas, 1971-73, Postdoctoral Fellowship in Tumor Immunology

### Employment History:

2013 - present Professor of Neurosurgery, School of Medicine, UAB  
2010 - present Co-Leader, Neuro-Oncology Program, CCC  
1998 - 2013 Professor of Surgery, School of Medicine, UAB  
1998 - present Associate Professor of Microbiology and of Cell Biology & Anatomy, School of Medicine, UAB  
1989-present Associate Professor of Cell Biology & Anatomy, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294  
1987-1998t Associate Professor of Surgery and of Microbiology, School of Medicine, UAB  
1987-present Scientist, Comprehensive Cancer Research Center, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294  
1982-1987 Research Associate Professor of Surgery and of Pathology, School of Medicine, University of North Carolina at Chapel Hill  
1981-1982 Research Assistant Professor of Surgery and of Pathology, School of Medicine, UNC-CH  
1979-1981 Research Assistant Professor of Pathology and of Surgery, School of Medicine, UNC-CH  
1979-1987 Member, Cancer Research Center, School of Medicine, UNC-CH  
1977-1979 Research Assistant Professor of Pathology, School of Medicine, UNC-CH  
1975-1977 Research Associate, Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California

1973-1975 Instructor, Department of Pathology and Oncology, University of Kansas School of Medicine, Kansas City, Kansas

### **Professional Organizations:**

American Association for the Advancement of Science  
American Association for Cancer Research  
American Association of Immunologists  
American Society of Investigative Pathology  
American Society of Microbiology  
Gordon S. Dugger Neurosurgical Society  
International Society for Biological Therapy of Cancer  
James Garber Galbraith Neurosurgical Society  
Society for Neuro-Oncology  
American Society of Gene Therapy

### **Professional Service:**

1979 - 1988 Editorial Board, *Yearbook of Pathology and Clinical Pathology*.  
1981-present Topic Editor, *Immunologic Research*.  
1990-present Member, Joint Committee on Tumors, American Association of Neurological Surgeons/Congress of Neurological Surgeons  
1993 - 1994 American Cancer Society Advisory Committee, Ad hoc reviewer  
1994-present Member, Medical Advisory Council, **American Brain Tumor Association**  
1995-1999 Scientific Advisory Board, **novopharm biotech, Ltd.**  
1996 NCI Site Visit Chairman, OSU Brain Tumor Program Project, October 11.  
1996 NCI IRG, Subcommittee E, December 9-10.  
1997-present, Member, Scientific Advisory Board, **The Brain Tumor Society**  
1997 NCI Review Panel - Clinical Cancer Therapy Research Grants, March 24-26.  
1998-2003 Scientific Advisory Board, **NeuroVir Therapeutics, Inc./Medigene, Inc.**  
1998-present Scientific Advisory Board, **Targepeutics, Inc.**  
1998-present Editorial Board, *Neuro-oncology*  
1998-present Editorial Board, *Journal of Neuro-Oncology*  
1999 NCI Review Panel – Therapeutic Modulation of Angiogenesis in Disease, February 17-19, 1999  
1999 Review Panel – Therapeutic Modulation of Angiogenesis in Disease, December 2-3, 1999.  
1999 -present, Member, Scientific Advisory Board, **The Pediatric Brain Tumor Foundation of the U.S.**  
2000 NINDS Review Panel – Neurological Sciences and Disorders-B, June 21-22.  
2000-present Member, Scientific Advisory Board, **Hermelin Brain Tumor Center**, Henry Ford Health System, Detroit, MI  
2000 NCI Review Panel – Interdisciplinary Research Teams for Molecular Target Assessment. September 28-29, 2000.  
2000 NCI Review Panel – Molecular Target Drug Discovery for Cancer, November 29, 2000.  
2001 NINDS Review Panel – Neurological Sciences and Disorders-B, February 22-23.  
2001 NCI Special Emphasis Review Group – RFA CA-01-020, November 13-14  
2002 NCI Cancer Center Support Review Group, New York University Cancer Institute, May 6-8.  
2003 Member, Scientific Advisory Board, **Tampa Bay Research Institute**  
2003 NINDS Review Panel – Neurological Sciences and Disorders-B, March 13-14.  
2003-2006 Member, Data Safety Monitoring Board, **Ceregene, Inc.**, San Diego, CA

2003-present	Chair, External Advisory Board, Brain Tumor Center of Excellence, Wake Forest University School of Medicine
2003	Cancer Center Support Review Group, Mayo Clinic Cancer Research Center, October 1-2, 2003
2004-present	Scientific Advisory Board, <b>T-VAX, Inc.</b> , Kansas City, MO
2004	NCI Cancer Center Support Review Group, University of Pittsburgh Cancer Institute, February
2004	NIH Special Emphasis Review Panel – Brain Disorders and Clinical Neurosciences-B (01), March 25
2004	NCI Initial Review Group Subcommittee A, Chevy Chase, MD, April 15
2004-2006	Member, Science Advisory Board, <b>SunBioChem, Inc.</b> , San Diego, CA
2004-	NCI, Special Emphasis Panel National Research Fellowships, July 19-20
2009-2012	NCI, Cancer Biomarkers Study Section
2012- present	Co-Chair, <i>National Brain Tumor Society</i> Scientific Advisory Board
2014 - present	Regional Advisory Network, Pediatric Brain Tumor Foundation of the U.S.

### **Committees:**

Neurosurgical Residency Recruitment and Education Committee, 1987 - present  
 Brain Tumor Program Protocol Committee, 1987-present  
 UAHSF Kirklin Clinic Purchasing Advisory Committee, 1994-1998  
 UAB IRB Gene Therapy Project Review Panel, 1998-present  
 Comprehensive Cancer Center Protocol Review Committee, 2011 - present

### **Other Administrative Activities:**

Director, Brain Tumor Research Laboratories, 1987-present  
 Director, UAB Brain Tumor SPORE, 2005 - present

### **Teaching Responsibility:**

#### **Postdoctoral Fellows:**

Ritchie P. Gillespie, M.D.; Research Trainee in Immunoneuro-oncology, 1980-1981  
 Mashimichi Shinonaga, M.D.; Postdoctoral Fellow in Immunoneuro-oncology, 1981-1982  
 John E. Estes, M.D.; Research Associate, 1981-1987  
 Stefan Pribil, M.D.; Research Trainee in Immunoneuro-oncology, 1982-1983  
 Scot C. Buessow, Ph.D.; Postdoctoral Fellow in Immunoneuro-oncology, 1983-1985  
 Yehia El-Hennawi, M.D.; Research Fellow in Immunoneuro-oncology, 1984-1985  
 David E. Tomaszek, M.D.; Research Trainee in Immunoneuro-oncology, 1985-1986  
 Daniel W. Fults, M.D.; Clinical Investigator in Immunoneuro-oncology, 1985 - 1987  
 Jun-Ichi Kuratsu, M.D., Ph.D.; Postdoctoral Fellow in Immunoneuro-oncology, 1986-1987  
 Corey K. Goldman, M.D.; Research Trainee in Neuro-Oncology, 1990-1994.  
 Nobuyuki Sueyoshi, M.D.; Postdoctoral Fellow in Neuro-Oncology, 1990-1991.  
 Jui-Chang Tsai, M.D.; Postdoctoral Fellow in Neuro-Oncology, 1992-1994.  
 James M. Markert, M.D., K08 Career Development Awardee, 1995-2000  
 Jacqueline N. Parker, Ph.D., Postdoctoral Fellow in Neuro-Oncology, 1998-2000.  
 C. Ryan Miller, M.D., Ph.D., Postdoctoral Fellow in Neuro-Oncology, 2000-2002  
 Corinne E. Griguer, Ph.D., Postdoctoral Fellow in Neuro-Oncology, 2003-2005.  
 Gregory K. Friedman, M.D., Postdoctoral Fellow in Neuro-Oncology, 2006-2008.  
 Elizabeth A. Beierle, M.D., K08 Career Development Awardee, 2008-2013  
 George Clement Dobbins, Ph.D., Postdoctoral Fellow in Neuro-Oncology, 2010-2014  
 Eric M. Thomas, M.D., Postdoctoral Fellow in Oncology, 2014 - 2015

#### **Predoctoral Students:** (\* thesis supervisor; advisor to others)

Conferred Degrees: *University of North Carolina at Chapel Hill*

1981- Dean Madar, Ph.D., M.D.; Departments of Chemistry and Pathology, UNC-CH  
 1983- Samy Iskandar, M.D., Ph.D.; Department of Pathology, UNC-CH  
 1983- Howard Katz, Ph.D.; Department of Microbiology and Immunology, UNC-CH  
 1984- Laura Livingstone, Ph.D.; Department of Biochemistry, UNC-CH

1985- Maureen Harrington, Ph.D.; Department of Pharmacology, UNC-CH  
1985- \*Bharat Gandhi, M.S.; Department of Pathology, UNC-CH, (M.D., 1989)  
1987- Rosemary Walsh, M.S.; Department of Biochemistry UNC-CH  
1988- Richard Rajia, DVM, Ph.D.; Department of Pathology, UNC-CH

Conferred Degrees: *The University of Alabama at Birmingham*

1989- John Bethea, Ph.D., Neurobiology Curriculum, UAB  
1993- \*Elaine Lyon, Ph.D., Medical Genetics Curriculum, UAB  
1993- Gavin Norris, Ph.D., Cell Biology & Anatomy, UAB  
1995- \*Mary A Tucker, Ph.D., Neurobiology Curriculum, UAB  
1996- Marc C. Daniels, Ph.D., Cell Biology & Anatomy, UAB  
1997- \*Corey K. Goldman, M.D., Cell Biology & Anatomy, UAB  
1997- Samita Sarkar Andreansky, Microbiology, UAB  
1997- Mary Ballestas, Cell Biology & Anatomy, UAB  
1997- Scott Drouin, Cellular & Molecular Biology Program, UAB  
1992- Jiyoun Kim, Biology, UA-Tuscaloosa (off-campus committee member)  
1992- Stephen C. Derrick, Biology, UA-Tuscaloosa (off-campus committee member)  
1995- Wolfgang Rohn, Cell Biology & Anatomy, UAB  
1999- Candece E. Clary, Physics, UAB  
1999- Hongwei Qin, Cell Biology, UAB  
2000 - Andrea Wolf, Microbiology, UAB  
2002 - Michael Ciesielski, Immunology, Roswell Park Cancer Institute (off-campus committee member)  
2002 Smaroula Dilioglou, Experimental Pathology, University of Mississippi Medical Center (off-campus committee member)  
2002 - Zhendong Ma, Cell Biology, UAB  
2005 - Rachael Reiman, Microbiology, UAB  
2005 - Mark Stonecypher, MSTP, Pathology, UAB  
2005 - Meera Natarajan, Molecular and Cellular Pathology, UAB  
2006 - Amish C. Shah, MSTP, Physiology and Biophysics, UAB  
2007 - Emily C. Brantley, Cell Biology, UAB  
2008 - David Gaston, MSTP, Cell Biology, UAB  
2010 - Edlira Bashari, Physiology And Biophysics, UAB  
2010 - Angelina I. Londono Joshi, Molecular and Cellular Pathology, UAB  
2012 - Michael Belenky, Biochemistry and Molecular Genetics, UAB  
2011 - Carl I. Odom, Cancer Cell Biology, UAB  
2012 - Latika Kohli, Molecular and Cellular Pathology, UAB  
2012 - Arun K. Roj, Physiology & Biophysics, UAB  
2013 - John Jarboe, Biochemistry & Molecular Genetics, UAB  
2014 - Niroop Kaza, Molecular and Cellular Pathology  
2014 - Stephanie Brosius, MSTP, Cancer Cell Biology  
2014 - Zachary C. Dobbin, MSTP, Cancer Cell Biology  
2015 - Vinayak Khattar, Cancer Cell Biology  
2015 - Tyrel T. Smith, Cancer Cell Biology  
2016 - Arindam P. Ghosh, Genetics and Genomics Sciences  
2016 - Christopher D. Graham, Cancer Cell Biology

Active Students:

2013 - Alex M. Dussaq, PPBM, MSTP  
2014 - Emily G. Thompson, Cell, Molecular & Developmental Biology  
2015 - Nicholas Eustace, Cancer Biology, MSTP  
2016 - \*Christian T. Stackhouse, Neuroscience  
2017 - Soniya Bastola, Cancer Biology

Courses:

PHY 755 Neuroimmunology, "*Immunobiology of brain tumors*", 1991, 1993

CB 713 Growth Factors Journal Club, Fall 1993 - Spring 1997; Fall 1998 - present.  
NEUR 780 Neurosciences Seminar, Fall 1996  
NBL 730 Neurobiology of Disease, "Molecular and cellular biology of malignant astroglial tumors" 1996, 1997  
Neurology Resident Conference – *Molecular biology of malignant glial neoplasms* 1/29/01  
VT 737 Graduate Level Brain Tumor (Glioma) Biology Course:  
    *Scientific Approaches to Addressing the Problem of Brain Tumor Research* 2/9/04  
    *Translational Research (Animal Models for Brain Tumor Research)* 3/8/04, 9/18/06,  
GBS 748 Graduate Level Brain Tumor Biology Course: *Animal Models*, 10/13/15

### **Patents and Inventions:**

United States Patent 6,552,005, *Molecular Chemotherapy Enhancement of Radiotherapy*, issued April 22, 2003.  
United States Patent 6,703,375, *Molecular Chemotherapy Enhancement of Radiotherapy*, issued March 9, 2004.  
United States Patent 6,764,675, *Herpes Simplex Virus Expressing Foreign Genes and Method for Treating Cancers Therewith*, issued July 20, 2004.

### **Publications:**

<http://www.ncbi.nlm.nih.gov/sites/myncbi/1jUpq189eqL5F/bibliography/43109936/public/?sort=date&direction=descending>

#### In Refereed Journals:

1. Cruse, J.M., J.T. Forbes, G.Y. Gillespie, and G.K. Lewis: Immunologic enhancement induced by antibody fragments. *Zeitschrift fur Immunitats-forschung, Allergie, und klinische Immunologie* **140**: 259-267, 1970.
2. Cruse, J.M., J.T. Forbes, B.R. Shivers, G.Y. Gillespie, G.K. Lewis, and R.B. Hester: A synergistic immunosuppressive effect of endotoxin and PHA-M on immunologic enhancement in mice. *Zeitschrift fur Immunitats-forschung, Allergie, and klinische Immunologie* **143**: 31-42, 1972.
3. Cruse, J.M., J.T. Forbes, G.Y. Gillespie, G.K. Lewis, R.W. Scales, B.R. Shivers, and R.B. Hester: Dissection of the immunosuppressive effects of the Fc region of tumor-enhancing IgG<sub>2</sub>. *Zeitschrift fur Immunitats-forschung, Allergie, and klinische Immunologie* **143**: 43-58, 1972.
4. Shivers, B.R., J.T. Forbes, J.M. Cruse, G.Y. Gillespie, and R.B. Hester: Stimulation and inhibition of non-immune lymphocyte-mediated cytotoxicity in vitro. *RES - Journal of the Reticuloendothelial Society* **12**: 257-282, 1972.
5. Barth, R.F., G.Y. Gillespie, and A. Gobuty: A new radioisotopic microcytotoxicity assay of cellular immunity employing technetium-99m. *National Cancer Institute Monograph* **35**: 39-41, 1972.
6. Gillespie, G.Y., R.F. Barth, and A. Gobuty: A new radioisotopic microassay of cell-mediated immunity utilizing technetium-99m labeled target cells. *Proceedings of the Society for Experimental Biology and Medicine* **142**: 378-383, 1972.
7. Gillespie, G.Y., R.F. Barth, and A. Gobuty: Labeling of mammalian nucleated cells with technetium-99m. *Journal of Nuclear Medicine* **14**: 706-708, 1973.
8. Barth, R.F., and G.Y. Gillespie: The use of technetium-99m as a radioisotopic label to assess cell-mediated immunity in vitro. *Cellular Immunology* **10**: 38-49, 1973.
9. Barth, R.F., and G.Y. Gillespie, and W. Rosenau: A radioisotopic microassay for lymphotoxin using technetium-99m labeled cells. *Proceedings of the Society for Experimental Biology and Medicine* **144**: 564-568, 1973.
10. Barth, R.F., O. Singla, and G.Y. Gillespie: The use of technetium-99m as a radioisotopic label to study the migratory patterns of normal and neoplastic cells. *Journal of Nuclear Medicine* **15**: 656-661, 1974.

11. Gillespie, G.Y., and R.F. Barth: Cyclic variations in cell-mediated immunity to skin allografts detected by the technetium-99m microcytotoxicity assay. *Cellular Immunology* **13**: 472-483, 1974.
12. Wood, G.W., G.Y. Gillespie, and R.F. Barth: Receptor sites for antigen-antibody complexes on tumor-derived cells. Detection by means of technetium-99m labeled, antibody-sensitized sheep erythrocytes. *Journal of Immunology* **114**: 950-957, 1975.
13. Wood, G.W., and G.Y. Gillespie: Studies on the role of macrophages in regulation of growth and metastasis of murine chemically induced fibrosarcomas. *International Journal of Cancer* **16**: 1022-1029, 1975.
14. Russell, S.W., G.Y. Gillespie, C.B. Hansen, and C.G. Cochrane: Inflammatory cells in solid murine neoplasms. II. Cell types found throughout the course of Moloney sarcoma regression and progression. *International Journal of Cancer* **18**: 331-338, 1976.
15. Hansen, C.B., G.Y. Gillespie, and S.W. Russell: Isolation of T lymphocytes from disaggregated tumors in high purity with good percentage recovery. *Journal of National Cancer Institute* **59**: 273-275, 1977.
16. Russell, S.W., G.Y. Gillespie, and A.T. McIntosh: Inflammatory cells in solid murine neoplasms. III. Cytotoxicity mediated in vitro by macrophages recovered from disaggregated regressing Moloney sarcomas. *Journal of Immunology* **118**: 1574-1579, 1977.
17. Gillespie, G.Y., C.B. Hansen, R.G. Hoskins, and S.W. Russell: Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney Sarcomas. *Journal of Immunology* **119**: 564-570, 1977.
18. Russell, S.W., and G.Y. Gillespie: Nature, function and distribution of inflammatory cells in regressing and progressing Moloney sarcomas. *Journal of Reticuloendothelial Society* **22**: 159-168, 1977.
19. Gillespie, G.Y., and S.W. Russell: Development and persistence of cytolytic T lymphocytes in regressing or progressing Moloney sarcomas. *International Journal of Cancer* **21**: 94-99, 1978.
20. Gillespie, G.Y., F.C. Jensen, and S.W. Russell: B-tropic oncornavirus production of BALB/c methylcholanthrene-induced sarcoma cells. *International Journal of Cancer* **21**: 234-238, 1978.
21. Gillespie, G.Y., C.B. Hansen, and S.W. Russell: Resurgence of killing and in vivo protection mediated by lymphocytes cultured from lymph nodes draining Moloney sarcomas. *British Journal of Cancer* **38**: 365-374, 1978.
22. Gillespie, G.Y., and R.F. Barth: Lymphocyte mediated reactivity against malignant melanoma detected by a microcytotoxicity assay employing technetium-99m labeled target cells. *Cancer* **41**: 2174-2182, 1978.
23. Gillespie, G.Y., and S.W. Russell: Level of activation determines whether inflammatory peritoneal and intratumoral macrophages will promote or suppress in vitro development of cytolytic T lymphocyte activity. *Journal of the Reticuloendothelial Society* **27**: 535-545, 1980.
24. Russell, S.W., G.Y. Gillespie, and J.L. Pace: Comparison of responses made to activating agents by mouse peritoneal macrophages and cells of the macrophage lines, RAW 264. *Journal of the Reticuloendothelial Society* **27**: 607-619, 1980.
25. Wharton, W., G.Y. Gillespie, S.W. Russell, and W.J. Pledger: Mitogenic activity elaborated by macrophage-like cell lines act as competence factor(s) for BALB/c-3T3 cells. *Journal of Cellular Physiology* **110**: 93-100, 1982.
26. Mahaley, M.S., Jr., G.Y. Gillespie, R.P. Gillespie, P.J. Watkins, D.D. Bigner, C.J. Wikstrand, J.M. MacQueen, and F. Sanfilippo: Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas. *Journal of Neurosurgery* **59**: 209-216, 1983.
27. Estes, J.E., W.J. Pledger, and G.Y. Gillespie: Macrophage-derived competence factor for fibroblasts and Interleukin-1 are distinct entities. *Journal of Leukocyte Biology* **35**: 115-129, 1984.
28. Earp, H.S., K.S. Austin, S.C. Buessow, R. Dy and G.Y. Gillespie: Membranes from T and B lymphocytes have different patterns of tyrosine phosphorylation. *Proceedings of the National Academy of Sciences (USA)* **81**: 2347-2351, 1984.

29. Buessow, S.C., G.Y. Gillespie, and M.S. Mahaley, Jr.: Tumoricidal activity of an acute promyelocytic leukemia cell line (HL-60) is augmented by human interferon alpha. *Leukemia Research* **8**: 801-811, 1984.
30. Buessow, S.C., and G.Y. Gillespie: Interferon alpha and gamma promote myeloid differentiation of HL-60, a human acute promyelocytic leukemia cell line. *Journal of Biological Response Modifiers* **3**: 653-662, 1984.
31. Mahaley, M.S., Jr., and G.Y. Gillespie: New therapeutic approaches to treatment of malignant gliomas: Chemotherapy and immunotherapy. *Clinical Neurosurgery* **31**: 456-469, 1984.
32. Loeffel, S.L., G.Y. Gillespie, S.A. Mirmiran, E.W. Miller, P. Golden, F.B. Askin, and G.S. Siegal: Cellular immunolocalization of S-100 protein specific monoclonal antibodies within fixed human tissue sections. *Archives of Pathology and Laboratory Medicine* **109**: 117-122, 1985.
33. Oliver, W.R., R.L. Reddick, G.Y. Gillespie, and G.S. Siegal: Juxtadrenal schwannoma mimicking an adrenocortical neoplasm. *Journal of Surgical Oncology* **30**: 259-268, 1985.
34. Earp, H.S., K.S. Austin, G.Y. Gillespie, S.C. Buessow, A.A. Davies, and P.J. Parker: Characterization of distinct tyrosine-specific protein kinases in B and T lymphocytes. *Journal of Biological Chemistry* **260**: 4351-4356, 1985.
35. Takiguchi, M., J.P.-Y. Ting, S.C. Buessow, C. Boyer, G.Y. Gillespie, and J.A. Frelinger: Response of glioma cells to gamma interferon: Increase in class II RNA, protein and MLR stimulating ability. *European Journal of Immunology* **15**: 809-814, 1985.
36. Bullard, D.E., G.Y. Gillespie, M.S. Mahaley, Jr., and D.D. Bigner: Immunobiology of human gliomas. *Seminars in Oncology* **13**: 94-109, 1986.
37. Malouf, N.N., S. Taylor, G.Y. Gillespie, J.M. Bynum, P.E. Wilson, and G. Meissner: Monoclonal antibody specific for the T-tubule of skeletal muscle. *Journal of Histochemistry and Cytochemistry* **34**: 346-355, 1986.
38. Powers, S.K., Pribil, S., Gillespie, G.Y. 3rd, Watkins, P.J. Laser photochemotherapy of rhodamine-123 sensitized human glioma cells in vitro. *J Neurosurg.* **64**: 918-923, 1986.
39. El-Hennawi, Y., G.Y. Gillespie, M.A. Varia, P. Watkins, M.S. Mahaley, Jr., and D.D. Bigner: Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomas. *Journal of Neuro-Oncology* **4**: 309-313, 1986.
40. Solleveld, H.A., D.D. Bigner, D.R. Averill, Jr., S.H. Bigner, G.A. Boorman, P.C. Burger, Y. Gillespie, G.B. Hubbard, O.D. Laerum, R.D. McComb, J.T. McGrath, K.T. Morgan, A. Peters, L.J. Rubinstein, B.S. Schoenberg, S.C. Schold, J.A. Swenberg, M.B. Thompson, M. Vandavelde, and S.A. Vinore: Brain tumors in man and animals: report of a workshop. *Environmental Health Perspectives* **68**: 155-173, 1986.
41. Gillespie, G.Y., J.J. Van Wyk, L.E. Underwood, M. Svoboda, and W.E. Russell: Derivation of monoclonal antibodies to human somatomedin-c/IGF-I. *Methods in Enzymology* **146**: 207-216, 1987.
42. Beckman, W.C., Jr., S.K. Powers, J.T. Brown, G.Y. Gillespie, D.D. Bigner, and J.L. Camps: Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo. *Cancer* **59**: 266-270, 1987.
43. El-Hennawi, Y., G.Y. Gillespie, M.S. Mahaley, Jr., D.D. Bigner: Treatment of autochthonous rat brain tumors with steroid plus heparin: A brief report. *Journal of Neuro-Oncology* **5**: 161-162, 1987.
44. Malouf, N.N., R. Coronado, G.Y. Gillespie, D. McMahon, and G. Meissner: Monoclonal antibody specific for the transverse tubular membrane of skeletal muscle activates the dihydropyridine-sensitive Ca<sup>2+</sup> channel. *Proceedings of the National Academy of Sciences (USA)* **84**: 5019-5022, 1987.
45. Banes, A.J., G.W. Link, A.G. Bevin, H.D. Peterson, G.Y. Gillespie, D. Bynum, S.L. Watts, and L. Dahners: Tendon synovial cells secrete fibronectin in vivo and in vitro. *Journal of Orthopaedic Research* **6**: 73-82, 1988.
46. Banes, A.J., K. Donlon, G.W. Link, G.Y. Gillespie, A.G. Bevin, H.D. Peterson, D. Bynum, S.L. Watts, and L. Dahners: Cell populations of tendon: A simplified method of isolation of tendon synovial cells and internal fibroblasts: Confirmation of origin and biological properties. *Journal of Orthopaedic Research* **6**: 83-94, 1988.

47. M.S. Mahaley, Jr., L. Bertsch, S. Cush, G.Y. Gillespie: Systemic gamma-interferon therapy for recurrent gliomas. *Journal of Neurosurgery* **69**: 826-829, 1988.
48. Kuratsu, J., J.E. Estes, S. Yokota, M.S. Mahaley, Jr. and G.Y. Gillespie: Growth factors derived from a human malignant glioma cell line, U-251MG. *Journal of Neuro-Oncology* **7**: 225-235, 1989.
49. McKenzie, R.A., M.J. Yablonski, G.Y. Gillespie and E.C. Theil: Cross-links between intramolecular pairs of ferritin subunits: Effects on both H and L subunits and on immunoreactivity of sheep spleen ferritin. *Archives of Biochemistry and Biophysics* **272**: 88-96, 1989.
50. Mahaley, M.S., Jr, S.W. Hipp, E.J. Dropcho, L. Bertsch, S. Cush, T. Tirey, G.Y. Gillespie: Intracarotid cisplatin chemotherapy for recurrent gliomas. *Journal of Neurosurgery* **70**: 371-378, 1989.
51. Mahaley, M.S., Jr., E.J. Dropcho, L. Bertsch, T. Tirey and G.Y. Gillespie: Systemic beta-interferon therapy for recurrent gliomas: a brief report. *Journal of Neurosurgery* **71**: 639-641, 1989.
52. El-Hennawi, Y., G.Y. Gillespie, M.S. Mahaley, Jr, M.A. Varia, D.D. Bigner, C. Stanton: A controlled study of efficacy of interstitial or external irradiation in a virus-induced brain-tumor model in rats. *Journal of Neurosurgery* **71**: 898-902, 1989.
53. Bethea, J.R., G.Y. Gillespie, I.Y. Chung and E.N. Benveniste: Tumor necrosis factor production and receptor expression by a human malignant glioma cell line, D54-MG. *Journal of Neuroimmunology* **30**: 1-13, 1990.
54. Mahaley, M.S., Jr., G.Y. Gillespie and R. Hammett: Computed tomography brain scan tumor volume determinations: sensitivity as an objective criterion of response to therapy. *Journal of Neurosurgery* **72**: 872-878, 1990.
55. Bethea, J.R., I.Y. Chung, S.M. Sparacio, G.Y. Gillespie and E.N. Benveniste: Interleukin-1 $\beta$  induction of tumor necrosis factor-alpha gene expression in human astrogloma cells. *Journal of Neuroimmunology* **36**: 179-191, 1991.
56. Dropcho, E.J., S.S. Rosenfeld, R.B. Morawetz, J. Vitek, M. Browthers, T. Gorum, S. Bell, G.Y. Gillespie, M. Glantz, M. S. Mahaley, Jr., and S.C. Schold, Jr.: Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. *Journal of Clinical Oncology* **10**: 452-458, 1992.
57. Bethea, J.R., G.Y. Gillespie and E.N. Benveniste: Interleukin-1 $\beta$  induction of TNF-alpha expression: involvement of protein kinase C. *Journal of Cell Physiology* **152**: 264-273, 1992.
58. Goldman, C.K., J. Kim, W.-L. Wong, V. King, T.A. Brock and G.Y. Gillespie: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. *Molecular Biology of the Cell* **4**: 121-133, 1993.
59. Lyon, E. and G.Y. Gillespie: Partial characterization of glioma-derived growth factor 2: A novel mitogenic activity from human cell line D-54 MG. *Journal of Neuro-Oncology* **17(2)**: 99-109, 1993.
60. Lyon, E. and G.Y. Gillespie: Monoclonal antibodies to glioma-derived growth factor(s). *Hybridoma* **13**: 15-20, 1994.
61. Tucker, M.A. and G.Y. Gillespie: Production of a Bioactive High Molecular Weight Transforming Growth Factor beta by Human Malignant Glioma Cell Lines. *Growth Factors* **11**: 153-162, , 1994.
62. Tsai, J.-C., C.K. Goldman and G.Y. Gillespie: Vascular Endothelial Growth Factor in Human Glioma Cell Lines: Induced Secretion by EGF, PDGF-BB and bFGF. *Journal of Neurosurgery* . **82**: 864-873, 1995.
63. Goldman, C.K. and G.Y. Gillespie: Physiological responsiveness of REVC, a continuous, diploid rabbit endothelial vascular cell line. *Journal of Vascular Research* **32**: 31-40, 1995.
64. Gladson, C.L., Pijuan, V., Olman, M.A., Gillespie, G.Y. and Yacoub, I.Z.: Upregulation of urokinase and urokinase receptor genes in malignant astrocytomas. *American Journal of Pathology* **146**: 1150-1160, 1995.
65. Chambers, R., Gillespie, G.Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., Whitley, R.J.: Comparison of genetically engineered herpes simplex

- viruses for the treatment of brain tumors in a *scid* mouse model of human malignant glioma. *Proceedings of the National Academy of Sciences, U.S.A.* **92**: 1411-1415, 1995.
66. Gladson, C.L., Wilcox, J.N., Sanders, L., Gillespie, G.Y. and Cheresh, D.A.: Cerebral microenvironment influences the expression of the vitronectin gene. *Journal of Cell Science* **108**: 947-956, 1995.
  67. Gillespie, G.Y., Goldman, C.K., Tsai, J.-C., Soroceanu, L. Loss of Vascular Endothelial growth factor in human alopecia hair follicles. *Journal of Investigative Dermatology* **104**(5, Suppl.): 18-20, 1995.
  68. Ullrich, N., Gillespie, G.Y., Sontheimer, H.: Human astrocytoma cells express a unique chloride current. *NeuroReports* **7**: 343-347, 1995.
  69. Raben, D., D.J. Buchsbaum, M.B. Khazaeli, M.E. Rosenfeld, G.Y. Gillespie, W.E. Grizzle, T. Liu, D.T. Curiel. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. *Gene Therapy* **3**: 567-580, 1996.
  70. Andreansky, S.S., He, B., Gillespie, G.Y., Soroceanu, L., Markert, J., Roizman, B. and Whitley, R.J.: The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. *Proceedings of the National Academy of Sciences, U.S.A.* **93**: 11313-11318, 1996.
  71. Andreansky, S., L. Soroceanu, E.R. Flotte, J. Chou, J.M. Markert, G.Y. Gillespie, B. Roizman, R.J. Whitley: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. *Cancer Research* **57**: 1502-1509, 1997.
  72. Clary, C.E., Dergachev, A., Mirov, S., Gillespie, G.Y.: Raman spectroscopic analysis of high grade malignant gliomas induced in *scid* mice. *Proc. SPIE* **2980**: 196-203, 1997.
  73. Goldman, C.K., L. Soroceanu, N. Smith, G.Y. Gillespie, W. Shaw, S. Burgess, G. Bilbao, D.T. Curiel: *In vitro* and *in vivo* gene delivery mediated by a synthetic polycationic amino polymer. *Nature Biotechnology* **15**: 462-466, 1997.
  74. Dan, M.D., Maiti, P.K., He, X., Gillespie, G.Y., Halliday, W.C., Prashar, A.K., Friesen, A.D., Kaplan, H.A.: Immunoreactivity of human monoclonal antibody BT32/A6 with neuroepithelial tumors. *Journal of Neuro-Oncology* **35**: 93-100, 1997.
  75. Goldman, C.K., S. Bharara, C. Palmer, J. Vitek and G.Y. Gillespie: Brain Edema in meningiomas is associated with increased VEGF expression. *Neurosurgery* **40**: 1269-1277, 1997:
  76. Parker, W.B., S.A. King, P.W. Allan, L.L. Bennett, Jr., J.A. Secrist, III, J.A. Montgomery, K.S. Gilbert, W.R. Waud, A.H. Wells, G.Y. Gillespie, E.J. Sorscher. *In vivo* gene therapy of cancer with *E. coli* purine nucleoside phosphorylase. *Human Gene Therapy* **8**: 1637-1644, 1997.
  77. Andreansky, S.S., B. He, J. Van Cott, J. McGhee, J.M. Markert, G.Y. Gillespie, B. Roizman, R.J. Whitley. Treatment of intracranial gliomas in immunocompetent mice using Herpes simplex viruses that express murine interleukins. *Gene Therapy*: **5**: 121-130, 1998.
  78. Ullrich, N., Bordey, A., Gillespie, G.Y., Sontheimer, H.W. Expression of voltage-activated chloride currents in acute slices of human gliomas. *Neuroscience* **83**: 1161-1173, 1998.
  79. Johanning, F.W., G.Y. Gillespie, J. Grim, C. Rancourt, R.D. Alvarez, G.P. Siegal, D.T. Curiel. Intracellular expression of a single-chain antibody directed against Human Papillomavirus type 16 E7 oncoprotein achieves targeted anti-neoplastic effects. *Cancer Research* **58**: 1893-1900, 1998.
  80. Tucker, M.A., P.-L. Chang, C.W. Prince, G.Y. Gillespie, T.B. Mapstone. TPA-mediated regulation of osteopontin in human malignant glioma cells. *Anticancer Res.* **18**: 807-812, 1998.
  81. Parker, W.B., P.W. Allan, S.C. Shaddix, L.M. Rose, H.F. Speegle, G.Y. Gillespie, L.L. Bennett, Jr. Metabolism and metabolic actions of 6-methyl purine and 2-fluoroadenine in human cells. *Biochem. Pharmacol.* **55**: 1673-1681, 1998.
  82. Goldman, C.K., R. Kendall, G. Cabrera, L. Soroceanu, Y. Heike, G.Y. Gillespie, G.P. Siegal, X. Mao, A.J. Bett, W.R. Huckle, K.A. Thomas and D.T. Curiel: Paracrine

- expression of the soluble VEGF receptor sFLT-1 inhibits tumor growth and metastasis. *Proceedings of the National Academy of Sciences* **95**: 8795-8800, 1998.
83. Soroceanu, L., Gillespie, G.Y., M.B. Khazaeli, H. Sontheimer. Use of chlorotoxin for targeting primary brain tumors. *Cancer Research* **58**: 4871-4879, 1998.
  84. Miller, C.R., D. J. Buchsbaum, P.N. Reynolds, J.T. Douglass, G.Y. Gillespie, M.S. Mayo, D. Raben, D.T. Curiel. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the Epidermal Growth Factor Receptor achieves fiber receptor-independent gene transfer. *Cancer Res.* **58**: 5738-5748, 1998.
  85. Gillespie, G.Y., L. Soroceanu, T.J. Manning, C.L. Gladson, S.S. Rosenfeld. Glioma migration can be blocked by nontoxic inhibitors of Myosin II. *Cancer Res* **59**: 2076-2082, 1999.
  86. Buben, J.K., D.A. Keeton, C.M. Fuller, G.Y. Gillespie, A.T. Reddy, T.B. Mapstone, D.J. Benos. Malignant human gliomas express an amiloride-sensitive Na<sup>+</sup> conductance. *American Journal of Physiology* **276**: *Cell Physiology* **45**: C1405-C1409, 1999.
  87. Debinski, W., D.M. Gibo, S.W. Hulet, J.R. Connor, G.Y. Gillespie. Receptor for Interleukin-13 is a marker and therapeutic target for human high grade gliomas. *Clinical Cancer Research* **5**: 985-990, 1999.
  88. Secrist, J.A., Parker, W.B., Allan, P.W., Bennett, L.L., Waud, W.R., Truss, J.W., Fowler, A.T., Montgomery, J.A., Ealick, S.E., Wells, A.H., Gillespie, G.Y., Gadi, V.K., Sorscher, E.J. Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. *Nucleosides Nucleotides*. **18**: 745-757, 1999.
  89. Bradley, J.D., Kataoka, Y., Advani, S., Chung, S.M., Arani, R.B., Gillespie, G.Y., Whitley, R.J., Markert, J.M., Roizman, B. and Weichselbaum, R.R. Ionizing radiation improves survival in mice bearing intracranial high grade gliomas injected with genetically modified herpes simplex virus. *Clinical Cancer Res.* **5**: 1517-1522, 1999.
  90. Advani, S.J., Chung, S.M., Yan, S.Y., Gillespie, G.Y., Markert, J.M., Whitley, R.J., Roizman, B. and Weichselbaum, R.R. Replication-competent non-neuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy resistant experimental human tumors. *Cancer Res.* **59**: 2055-2058, 1999.
  91. Debinski, W., D.M. Gibo, B. Slagle, S.K. Powers, G.Y. Gillespie. Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme. *International Journal of Oncology* **15**: 481-486, 1999.
  92. Markert, J.M., G.Y. Gillespie, R.R. Weichselbaum, B. Roizman, R.J. Whitley. Genetically engineered HSV in the treatment of glioma: A review. *Rev. Med. Virol.* **10**: 17-30, 2000.
  93. Chatterjee, S., S. A. Matsumura, J. Schradermeier, G.Y. Gillespie. Human malignant glioma therapy using anti- $\alpha_v\beta_3$  integrin agents. *J. Neuro-Oncol.* **46**: 135-144, 2000.
  94. Parker, J.N., G.Y. Gillespie, C.E. Love, S. Randall, R.J. Whitley, J.M. Markert. Engineered herpes simplex virus expressing interleukin 12 in the treatment of experimental murine brain tumors. *Proc. Natl Acad. Sci USA* **97**: 2208-2213, 2000.
  95. Markert, J.M., M.D. Medlock, S.D. Rabkin, G.Y. Gillespie, T. Todo, W.D. Hunter, C.A. Palmer, F. Feigenbaum, C. Tornatore, F. Tufaro, R.L. Martuza. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. *Gene Therapy* **7**: 867-874, 2000.
  96. Bledsoe, A.W., G.Y. Gillespie, C.D. Morrow. Targeted foreign gene expression in spinal cord neurons using poliovirus replicons. *Journal of Neurovirology* **6**: 95-105, 2000.
  97. Ghanta, V.K., Hiramoto, N.S., Gillespie, G.Y., Gauthier, D.K., Hiramoto, R.N. Immunotherapy of a murine T cell lymphoma localized to the brain. *J Neurooncol* **47**: 1-10, 2000.
  98. Debinski, W., Slagle, B., Gibo, D.M., Powers, S.K., Gillespie, G.Y. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. *J Neurooncol.* **48**: 103-111, 2000
  99. Markert, J.M., J.N. Parker, G.Y. Gillespie, R.J. Whitley. Genetically engineered human herpes simplex virus in the treatment of brain tumours. *Herpes* **8**: 10 – 16, 2001.
  100. Markert, J.M., C.M. Fuller, G.Y. Gillespie, J.K. Buben, L.A. McLean, R.L. Hong, L-L. Hsiao, S.R. Gullans, T.B. Mapstone, D.J. Benos. Differential gene expression in human brain tumors. *Physiologic Genomics* **5**: 21-33, 2001.
  101. Nabors, L.B., G.Y. Gillespie, L. Harkins, P.H. King. HuR, a RNA stability factor, is

- expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic mRNAs. *Cancer Res.* **61**: 2154-2161, 2001.
102. Cobbs C.S., Samanta, M., Harkins, L.E., Gillespie, G.Y., Merrick, B.A., MacMillan-Crow, L.A. Evidence for peroxynitrite-mediated modifications to p53 in human gliomas: possible functional consequences. *Arch Biochem Biophys.* **394**: 167-72, 2001.
  103. Choi, C. X. Xu, J.-W. Oh, S.J. Lee, G.Y. Gillespie, H. Park, H. Jo, E.N. Benveniste Fas-induced expression of chemokines in human glioma cells: Involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. *Cancer Res.* **61**: 3084-3091, 2001.
  104. Berdiev, B.K., T.B. Mapstone, J.M. Markert, G.Y. Gillespie, J. Lockhar, C.M. Fuller, D.J. Benos. pH alterations 'reset' Ca<sup>2+</sup> sensitivity of BNAC2, a DEG/EnaC ion channel, in planar lipid bilayers. *J. Biol. Chem.* **276**: 38755-61, 2001.
  105. Debinski, W., B. Slagle, M.G. Achen, S.A. Stacker, E. Tulchinsky, G.Y. Gillespie, D.M. Gibo. VEGF-D is an X-linked/AP-1 regulated onco-angiogen in human glioblastoma multiforme. *Molecular Medicine* **7**: 598-608, 2001.
  106. Ansardi, D.A., Porter, D.C., C.A. Jackson, Gillespie, G.Y., Morrow, C.D. RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins. *Cancer Res.* **61**: 8470-8479, 2001.
  107. Cassady, K.A., M. Gross, G.Y. Gillespie, B. Roizman. Second-site mutation outside of the Us10-12 domain of  $\Delta\gamma_134.5$  herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase R and partially restores neurovirulence. *J. Virol.* **76**: 942-949, 2002.
  108. Chung, S.-M., S.J. Advani, J.D. Bradley, Y. Kataoka, K. Vashistha, S.Y. Yan, J.M. Markert, G.Y. Gillespie, R.J. Whitley, B. Roizman, R.R. Weichselbaum. The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. *Gene Therapy* **9**: 75-80, 2002
  109. Miller, C.R., Williams, C.R., Buchsbaum, D.J., Gillespie, G.Y. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. *Cancer Res.* **62**: 773-780, 2002.
  110. Choi, C., G.Y. Gillespie, N.J. Van Wagoner, E.N. Benveniste. Fas engagement increases expression of Interleukin-6 in human glioma cells. *J. Neuro-Oncol.* **56**: 13-19, 2002.
  111. Hecker, T.P., Grammer, J.R., Gillespie, G.Y., Stewart, J. Jr., Gladson, C.L. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. *Cancer Res.* **62**: 2699-2707, 2002.
  112. Cobbs, C.S., Harkins, L., Samanta, M., Gillespie, G.Y., Bharara, S., King, P.H., Nabors, L.B., Cobbs, C.G., Britt. W.J. Human cytomegalovirus infection and expression in human malignant gliomas. *Cancer Res.* **62**: 3347-3350, 2002.
  113. Kabilerov, S., D.J. Buchsbaum, G.Y. Gillespie, D.T. Curiel, W.O. Arafat, M.A. Stackhouse. Adenovirus-mediated transfer of Bax driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. *Molecular Therapy* **6**: 190-198, 2002.
  114. Berdiev, B.K., J. Xia, B. Jovov, J. M. Markert, T. B. Mapstone, G.Y. Gillespie, C.M. Fuller, J. K. Bubien, and D.J. Benos. Protein kinase C isoform antagonism controls BNAC2 (ASIC1) function. *J Biol Chem.* **277(48)**: 45734-45740, 2002.
  115. Blanquicett, C., G.Y. Gillespie, L.B. Nabors, C.R. Miller, S. Bharara, D.J. Buchsbaum, R.B. Diasio, M.R. Johnson Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using Capecitabine and irradiation. *Molecular Cancer Therapeutics* **1**: 1139-1145, 2002.
  116. Berdiev, B.K., J. Xia, L.-A. McLean, J.M. Markert, G. Y. Gillespie, T. B. Mapstone, A. P. Naren, B. Jovov, J.K. Bubien, H.-L. Ji, C. M. Fuller, K. L. Kirk, and D.J. Benos. Acid-sensing ion channels in malignant gliomas. *J. Biol. Chem.*, **278**: 15023-15034, 2003.
  117. Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, Arani R, Chen DT, Carpenter M, Raisch KP. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. *Bioconjug Chem.* **14(2)**: 302-310,

- 2003.
118. Xia, J., Z.-H. Zhou, J. K. Bubien, C.M. Fuller, J.M. Markert, T. B. Mapstone, G.Y. Gillespie, and D.J. Benos. Molecular cloning and characterization of human ASIC2 gene promoter. *Gene*, **313**: 91-101, 2003.
  119. Tsai JC, Teng LJ, Chen CT, Hong TM, Goldman CK, Gillespie GY. Protein kinase C mediates induced secretion of vascular endothelial growth factor by human glioma cells. *Biochem Biophys Res Commun*. **309(4)**: 952-960, 2003.
  120. Shah, A.C., D. Benos, G.Y. Gillespie, J.M. Markert. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. *J. Neuro-Oncol.* **65**: 203-226, 2003.
  121. Bubien J.K., H.L. Ji, G.Y. Gillespie, C.M. Fuller, J.M. Markert, T.B. Mapstone, D.J. Benos. Cation selectivity and inhibition of malignant glioma Na<sup>+</sup> channels by Psalmotoxin1. *Am J Physiol Cell Physiol*. **287(5)**: C1282-91, 2004.
  122. Yamini B, Yu X, Gillespie GY, Kufe DW, Weichselbaum RR. Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. *Cancer Res*. **64(18)**: 6381-6384, 2004.
  123. Parker, J.N., S. Meleth, K.B. Hughes, G.Y. Gillespie, R.J. Whitley, J.M. Markert. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. *Cancer Gene Therapy* **12(4)**: 359-368, 2005.
  124. Shen S, Khazaeli MB, Gillespie GY, Alvarez VL. Radiation dosimetry of (131)I-chlorotoxin for targeted radiotherapy in glioma-bearing mice. *J Neurooncol*. **71(2)**: 113-119, 2005.
  125. Griguer, C.E., Oliva, C.R., Gillespie, G.Y. Glucose metabolism heterogeneity in malignant glioma: LDH-B, a potential marker for slow growing experimental glioma. *J. Neurooncol*. **74(2)**: 123-133, 2005.
  126. Hellums, E.K., Randall, S.H., Markert, J.M., Parker, J.N., He, B., Perbal, B., Roizman, B., Whitley, R.J., Gillespie, G.Y. Increased efficacy of an IL12-secreting HSV in a syngeneic intracranial murine glioma model suitable for immunologic and non-immunologic evaluation of mutant HSV-1 therapy. *Neuro-Oncology* **7**: 213-224, 2005.
  127. Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H. Inhibition of cystine uptake disrupts the growth of primary brain tumors. *J Neurosci*. **25(31)**: 7101-7110, 2005.
  128. Kovacs, G.G., Zsembergy, A., Anderson, S.J., Komlosi, P., Gillespie, G.Y., Bell, P.D., Benos, D.J., Fuller, C.M. Changes in intracellular calcium and pH in response to thapsigargin in human glioblastoma cells and normal astrocytes. *Am J Physiol Cell Physiol*. **289(2)**: C361-371, 2005.
  129. Bharara S, Sorscher EJ, Gillespie GY, Lindsey JR, Hong JS, Curlee KV, Allan PW, Gadi VK, Alexander SA, Secrist JA 3rd, Parker WB, Waud WR. Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy. *Hum Gene Ther*. **16(3)**: 339-347, 2005.
  130. Stettner, M.R., Wang, W. Nabors, L.B., Bharara, S., Flynn, D.C., Grammer, J.R., Gillespie, G.Y., Gladson, C.L. Lyn kinase activity is the predominant cellular src kinase activity in glioblastoma tumor cells. *Cancer Res*. **65(13)**: 5535-5543, 2005.
  131. Banks, J.T., Bharara, S., Tubbs, R.S., Wolff, C.L., Gillespie, G.Y., Markert, J.M., Blount, J.P. Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infections. *Neurosurgery* **57(6)**: 1237-1243, 2005.
  132. Chen, S.-H., G.Y. Gillespie, E.N. Benveniste. Divergent effects of Oncostatin M on astroglia cells: Influence on cell proliferation, invasion, and expression of matrix metalloproteinases. *Glia* **53(2)**: 191-200, 2006.
  133. Parker, J.N., Pfister, L.A., Quenelle, D., Gillespie, G.Y., Markert, J.M., Kern, E.R., Whitley, R.J. Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. *Vaccine* **24**: 1644-1652, 2006.
  134. Akella, N.S., Q. Ding, I.M. Menegazzo, W. Wang, G.Y. Gillespie, J.R. Grammar, C.L. Gladson, L.B. Nabors. A novel technique to quantify glioma tumor invasion using serial microscopy sections, *Journal of Neuroscience Methods* **153**: 183-189, 2006.
  135. Griguer, C.E., C.R. Oliva, E.E. Kelley, G.I. Giles, J.R. Lancaster, Jr, G.Y. Gillespie Xanthine Oxidase-dependent Regulation of Hypoxia-Inducible Factor in Cancer Cells.

- Cancer Res.* **66(4)**: 2257-2263, 2006.
136. Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, Lattera J. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. *Clin Cancer Res.* **12(4)**:1292-1298, 2006.
  137. Grunda, J.M., L.B. Nabors, C.A. Palmer, D.C. Chhieng, A.D. Steg, T. Mikkelsen, R.B. Diasio, K. Zhang, D. Allison, W.E. Grizzle, W. Wang, G.Y. Gillespie, M.R. Johnson. Increased Expression of Thymidylate Synthetase (TS), Ubiquitin Specific Protease 10 (USP10) and Survivin is Associated with Poor Survival in Glioblastoma Multiforme (GBM). *Journal of Neuro-Oncology* **80(3)**: 261-274, 2006.
  138. Guffey, M.B. J.N. Parker, W.S. Lockett, Jr., G.Y. Gillespie, S. Meleth, R.J. Whitley, J.M. Markert. Engineered Herpes Simplex Virus Expressing Bacterial Cytosine Deaminase for Experimental Therapy of Brain Tumors *Cancer Gene Therapy* **14(1)**: 45-56., 2007.
  139. Shah, A.C., K.H. Price, J.N. Parker, S.L. Samuel, S. Meleth, K.A. Cassady, G.Y. Gillespie, R.J. Whitley, J.M. Markert. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. *J. Virol.* **80(15)**: 7308-7315, 2006.
  140. Vila-Carriles WH, Kovacs GG, Jovov B, Zhou ZH, Pahwa AK, Colby G, Esimai O, Gillespie GY, Mapstone TB, Markert JM, Fuller CM, Bubien JK, Benos DJ. Surface expression of ASIC2 inhibits the amiloride sensitive current and migration of glioma cells. *J Biol Chem.* **281(28)**: 19220-19232, 2006.
  141. Markert, J., Parker, J., Buchsbaum, D.J., Grizzle, W., Gillespie, G.Y., Whitley, R. Oncolytic HSV-1 for the Treatment of Brain Tumours. *Herpes.* **13(3)**: 66-71, 2006. PMID: 17147910.
  142. C.E. Griguer, C.R. Oliva, G.Y. Gillespie. Pharmacologic Manipulations of Mitochondrial Membrane Potential ( $\Delta\psi$ ) Selectively in Glioma Cells. *J. Neuro-Oncol.* **81(1)**: 9-20., 2007. PMID: 16862448
  143. Khwaja, F.W., M.S. Reed, J.J. Olson, B.J. Schmotzer, G.Y. Gillespie, A. Guha, M.D. Groves, S. Kesari, J. Pohl, E.G. Van Meir. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. *J. Proteome Res.* **6(2)**: 559-570, 2007. PMID: 17269713
  144. Radbill, A.E., A.T. Reddy, J.M. Markert, J.M. Wyss, M.M. Pike, N.S. Akella, N. Bharara, G.Y. Gillespie. Effects of G207, a Conditionally Replication-Competent Oncolytic Herpes Simplex Virus, on the Developing Mammalian Brain. *Journal of NeuroVirology* **13(2)**:118-29, 2007.
  145. Tang, Y., Han, T., Everts, M., Zhu, Z.B., Gillespie, G.Y., Curiel, D.T., Wu, H. Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. *Gene Ther.* **14(6)**: 523-532, 2007. PMID: 17167498
  146. Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. *Gene Ther.* **14(13)**: 1045-1054, 2007. PMID: 17429445
  147. Kaliberov SA, Market JM, Gillespie GY, Krendelchtchikova V, Della Manna D, Sellers JC, Kaliberova LN, Black ME, Buchsbaum DJ. Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma. *Gene Ther.* **14(14)**: 1111-1119, 2007. PMID: 17495948
  148. Van Houdt, W.J., Wu, H., Glasgow, J., Lamfers, M., Dirven, C., Gillespie, G.Y., Curiel, D.T., Haviv, Y. Gene delivery into malignant glioma by infectivity-enhanced adenovirus: In vivo vs. in vitro models. *Neuro-Oncology*, **9(3)**:280-290, 2007 PMID: 17522331
  149. Forsyth, P., Roldán, G., George, D., Wallace, C., Palmer, C.A., Morris, D., Cairncross, J.G., Matthews, M.V., Markert, J.M., Gillespie, Y., Coffey, M., Thompson, B., Hamilton, M. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. *Mol. Ther.* **16(3)**: 627-632, 2008. PMID: 18253152
  150. Suswam E, Li Y, Zhang X, Gillespie GY, Li X, Shacka JJ, Lu L, Zheng L, King PH. Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. *Cancer Res.* **68(3)**: 674-682, 2008. PMID: 18245466
  151. Kaliberov SA, Markert JM, Gillespie GY, Krendelchtchikova V, Manna DD, Sellers JC,

- Kaliberova LN, Black ME, Buchsbaum DJ (Letter to Editor) Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma. *Gene Ther.* **15(4)**: 327, 2008.
152. Fiveash JB, **Gillespie GY**, Oliver PG, Zhou T, Belenky ML, Buchsbaum DJ. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. *Int J Radiat Oncol Biol Phys.*; **71(2)**: 507-516, 2008. PMID: 18474311
  153. Brantley EC, Nabors LB, **Gillespie GY**, Choi YH, Palmer CA, Harrison K, Roarty K, Benveniste EN. Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. *Clin Cancer Res.* **14(15)**:4694-4704, 2008. PMID: 18676737
  154. Fiveash J, Buchsbaum D, **Gillespie GY**. In Reply to Dr. Speer. *Int J Radiat Oncol Biol Phys.* ; **72(4)**:1274, 2008. PMID: 18954728]
  155. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, **Gillespie GY**. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. *Mol Ther.* **17(1)**: 199-207, 2009. PMID: 18957964
  156. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr, **Gillespie GY**. CD133 is a marker of bioenergetic stress in human glioma. *PLoS ONE*. 2008;3(11):e3655. Epub 2008 Nov 5. PMID: 18985161
  157. Bryant NL, Suarez-Cuervo C, **Gillespie GY**, Markert JM, Nabors LB, Meleth S, Lopez RD, Lamb LS Jr. Characterization and immunotherapeutic potential of  $\{\gamma\}\{\delta\}$  T cells in patients with glioblastoma. *Neuro Oncol.* **11(4)**: 357-367, 2009. PMC2743216.
  158. Northcott, P.A., Nakahara, Y., Wu, X., Feuk, L., Ellison, D.W., Croul, S., Mack, S., Kongkham, P.N., Peacock, J., Dubuc, A., Ra, Y-S., Zilberberg, K., McLeod, J., Scherer, S.W., Rao, J. S., Eberhart, C.G., Grajkowska, W., **Gillespie, Y.**, Lach, B., Greudy R., Pollack, I.AF., Hamilton, R.J., Meter, T.V., Carlotti, C.G., Boop, F., Bigner, D., Bilbertson, R.J., Rutka, J.T., Taylor, M.D. [Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.](#) *Nature Genetics* **41(4)**: 465-472, 2009. PMID: 19270706
  159. Pike MM, Stoops CN, Langford CP, Akella NS, Nabors LB, **Gillespie GY**. High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI. *Magn Reson Med.* **61(3)**: 615-625, 2009. PMID: 19235262
  160. Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, **Gillespie Y**, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD. [The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.](#) *Cancer Res.* **69(8)**: 3249-3255, 2009 PMID: 19351822; PMCID: PMC2836891
  161. Kaliberova LN, Krendelchtchikova V, Harmon DK, Stockard CR, Petersen AS, Markert JM, **Gillespie GY**, Grizzle WE, Buchsbaum DJ, Kaliberov SA. CRAdRGDflit-IL24 virotherapy in combination with chemotherapy of experimental glioma. *Cancer Gene Ther.* **16(10)**: 794-805, 2009 PMID: 19363468
  162. Friedman GK, Pressey JG, Reddy AT, Markert JM, **Gillespie GY**. Herpes simplex virus oncolytic therapy for pediatric malignancies. *Mol Ther.* **17(7)**:1125-1135, 2009. PMID: 19367259
  163. Friedman GK, Langford CP, Coleman JM, Cassady KA, Parker JN, Markert JM, **GY Gillespie**. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. *J Neurooncol.* **95(2)**: 199-209, 2009. PMID: 19521665
  164. Nabors LB, Fiveash JB, Markert JM, Kekan MS, **Gillespie GY**, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. *Arch Neurol.* 2010 **67(3)**:313-319. PMID: 20212229
  165. Bryant NL, **Gillespie GY**, Lopez RD, Markert JM, Cloud GA, Langford CP, Arnouk H, Su

- Y, Haines HL, Suarez-Cuervo C, Lamb LS Jr. Preclinical evaluation of ex vivo expanded/activated gamma delta T cells for immunotherapy of glioblastoma multiforme. *J Neurooncol.* **101(2)**:179-88, 2011 PMID: 20532954
166. Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB, Rand V, Leary SE, White E, Eden C, Hogg T, Northcott P, Mack S, Neale G, Wang YD, Coyle B, Atkinson J, DeWire M, Kranenburg TA, **Gillespie Y**, Allen JC, Merchant T, Boop FA, Sanford RA, Gajjar A, Ellison DW, Taylor MD, Grundy RG, Gilbertson RJ. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. *Nature.* 2010 Jul 29;466(7306):632-6. Epub 2010 Jul 18. PMID: 20639864
167. Oliva CR, Nozell SE, Diers A, McClugage SG 3rd, Sarkaria JN, Markert JM, Darley-Usmar VM, Bailey SM, **Gillespie GY**, Landar A, Griguer CE. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. *J Biol Chem.* **285(51)**: 39759-39767, 2010. PMID: 20870728
168. Friedman GK, **Gillespie GY**. Cancer Stem Cells and Pediatric Solid Tumors. *Cancers*, **3(1)**: 298-318, 2011. doi:[10.3390/cancers3010298](https://doi.org/10.3390/cancers3010298) PMID: 21394230.
169. Sun M, Song L, Zhou T, **Gillespie GY**, Jope RS. The role of DDX3 in regulating Snail. *Biochim Biophys Acta.* **1813(3)**: 438-447, 2011. PMID: 21237216
170. Filippova N, Yang X, Wang Y, **Gillespie GY**, Langford C, King PH, Wheeler C, Nabors LB. The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance. *Mol Cancer Res.* ;9(5):648-659, 2011 PMID: 21498545
171. Advani SJ, Markert JM, Sood RF, Samuel S, **Gillespie GY**, Shao MY, Roizman B, Weichselbaum RR. Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. *Gene Ther.* 2011 May 5. [Epub ahead of print] PMID: 21544094
172. Wang D, Olman MA, Stewart J Jr, Tipps R, Huang P, Sanders PW, Toline E, Prayson RA, Lee J, J Weil R, Palmer CA, **Gillespie GY**, Liu WM, Pieper RO, Guan JL, Gladson CL. [Downregulation of FIP200 Induces Apoptosis of Glioblastoma Cells and Microvascular Endothelial Cells by Enhancing Pyk2 Activity.](#) *PLoS One.* 2011;6(5):e19629. Epub 2011 May 13. PMID: 21602932.
173. Oliva CR, Moellering DR, **Gillespie GY**, Griguer CE. [Acquisition of Chemoresistance in Gliomas Is Associated with Increased Mitochondrial Coupling and Decreased ROS Production.](#) *PLoS One.* 2011;6(9):e24665. Epub 2011 Sep 9.
174. McFarland BC, Ma JY, Langford CP, **Gillespie GY**, Yu H, Zheng Y, Nozell SE, Huszar D, Benveniste EN. [Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma.](#) *Mol Cancer Ther.*;10(12):2384-93, 2011. PMID: 22027691 PMID: PMC3237864
175. Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, Vaughan LK, Mehta T, McCubrey RO, Khodarev NN, Weichselbaum RR, **Gillespie GY**. [Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner.](#) *PLoS One.* 2012;7(1):e29653. Epub 2012 Jan 5. PMID: 22242177
176. Markert JM, Cody JJ, Parker JN, Coleman JM, Price KH, Kern ER, Quenelle DC, Lakeman AD, Schoeb TR, Palmer CA, Cartner SC, **Gillespie GY**, Whitley RJ. [Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.](#) *J Virol.* 2012 May;86(9):5304-13. Epub 2012 Feb 29. PMID: 22379082
177. Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, **Gillespie GY**, Friedman GK. [CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.](#) *Pediatr Blood Cancer.* 2012 Mar 9. doi: 10.1002/pbc.24117. [Epub ahead of print] PMID: 22408058
178. Friedman GK, Cassady KA, Beierle EA, Markert JM, **Gillespie GY**. [Targeting pediatric cancer stem cells with oncolytic virotherapy.](#) *Pediatr Res.* 2012 Apr;71(4 Pt 2):500-10. doi: 10.1038/pr.2011.58. Epub 2012 Feb 15. PMID: 22430386
179. Jarboe JS, Anderson JC, Duarte CW, Mehta T, Newsheen S, Hicks PH, Whitley AC, Rohrbach TD, McCubrey RO, Chiu S, Burleson TM, Bonner JA, **Gillespie GY**, Yang ES, Willey CD. [MARCKS Regulates Growth and Radiation Sensitivity and Is a Novel](#)

- [Prognostic Factor for Glioma.](#) Clin Cancer Res. 2012 Jun 1;18(11):3030-41. Epub 2012 May 22. PMID: 22619307
180. Friedman GK, Haas MC, Kelly VM, Markert JM, **Gillespie GY**, Cassady KA. [Hypoxia Moderates  \$\gamma\(1\)34.5\$ -Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures.](#) Transl Oncol. 2012 Jun;5(3):200-7. Epub 2012 Jun 1. PMID: 22741039; PMC3384274
181. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A, Cavalli FM, Wang X, Remke M, Wu X, Chiu RY, Chu A, Chuah E, Corbett RD, Hoad GR, Jackman SD, Li Y, Lo A, Mungall KL, Nip KM, Qian JQ, Raymond AG, Thiessen NT, Varhol RJ, Birol I, Moore RA, Mungall AJ, Holt R, Kawauchi D, Roussel MF, Kool M, Jones DT, Witt H, Fernandez-L A, Kenney AM, Wechsler-Reya RJ, Dirks P, Aviv T, Grajkowska WA, Perek-Polnik M, Haberler CC, Delattre O, Reynaud SS, Doz FF, Pernet-Fattet SS, Cho BK, Kim SK, Wang KC, Scheurlen W, Eberhart CG, Fèvre-Montange M, Jouvét A, Pollack IF, Fan X, Muraszko KM, **Gillespie GY**, Di Rocco C, Massimi L, Michiels EM, Kloosterhof NK, French PJ, Kros JM, Olson JM, Ellenbogen RG, Zitterbart K, Kren L, Thompson RC, Cooper MK, Lach B, McLendon RE, Bigner DD, Fontebasso A, Albrecht S, Jabado N, Lindsey JC, Bailey S, Gupta N, Weiss WA, Bognár L, Klekner A, Van Meter TE, Kumabe T, Tominaga T, Elbabaa SK, Leonard JR, Rubin JB, Liau LM, Van Meir EG, Fouladi M, Nakamura H, Cinalli G, Garami M, Hauser P, Saad AG, Iolascon A, Jung S, Carlotti CG, Vibhakar R, Ra YS, Robinson S, Zollo M, Faria CC, Chan JA, Levy ML, Sorensen PH, Meyerson M, Pomeroy SL, Cho YJ, Bader GD, Tabori U, Hawkins CE, Bouffet E, Scherer SW, Rutka JT, Malkin D, Clifford SC, Jones SJ, Korbel JO, Pfister SM, Marra MA, Taylor MD. [Subgroup-specific structural variation across 1,000 medulloblastoma genomes.](#) Nature. 2012 Aug 2;488(7409):49-56. PMID: 22832581.
182. Lamb LS Jr, Bowersock J, Dasgupta A, **Gillespie GY**, Su Y, Johnson A, Spencer HT (2013) Engineered Drug Resistant  $\gamma\delta$  T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy. PLoS ONE 8(1): e51805. doi:10.1371/journal.pone.0051805
183. Cody, JJ, Scaturro, P, Cantor, AB, **Gillespie, GY**, Parker, JN, Markert, JM. [Preclinical Evaluation of Oncolytic  \$\Delta\gamma\(1\)34.5\$  Herpes Simplex Virus Expressing Interleukin-12 for Therapy of Breast Cancer Brain Metastases](#) Int J Breast Cancer. 2012;2012:628697. doi: 10.1155/2012/628697. Epub 2012 Dec 31. PMID: 23346408; PMCID: PMC3549352
184. Friedman GK, Raborn J, Kelly VM, Cassady KA, Markert JM, **Gillespie GY**. [Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy.](#) Front Oncol. 2013;3:28. doi: 10.3389/fonc.2013.00028. Epub 2013 Feb 28. PMID: 23450706
185. Griguer CE, Cantor AB, Fathallah-Shaykh HM, **Gillespie GY**, Gordon AS, Markert JM, Radovanovic I, Clement-Schatlo V, Shannon CN, Oliva CR. [Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme.](#) PLoS One. 2013 Apr 10;8(4):e61035. doi: 10.1371/journal.pone.0061035. Print 2013. PMID: 23593382
186. Knight A, Arnouk H, Britt W, **Gillespie GY**, Cloud GA, Harkins L, Su Y, Lowdell MW, Lamb LS. [CMV-Independent Lysis of Glioblastoma by Ex Vivo Expanded/Activated  \$V\delta 1+\$   \$\gamma\delta\$  T Cells.](#) PLoS One. 2013 Aug 7;8(8):e68729. doi: 10.1371/journal.pone.0068729. PMID: 23950874. PMCID: PMC3737218
187. Gillory LA, Megison ML, Stewart JE, Mroczek-Musulman E, Nabers HC, Waters AM, Kelly V, Coleman JM, Markert JM, **Gillespie GY**, Friedman GK, Beierle EA. [Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma.](#) PLoS One. 2013 Oct 10;8(10):e77753. doi: 10.1371/journal.pone.0077753. PMID: 24130898

188. Lobo MR, Green SC, Schabel MC, **Gillespie GY**, Woltjer RL, Pike MM. [Quinacrine synergistically enhances the antivasular and antitumor efficacy of cediranib in intracranial mouse glioma.](#) Neuro Oncol. 2013 Dec;15(12):1673-83. doi: 10.1093/neuonc/not119. Epub 2013 Oct 3. PMID: 24092859
189. Megison ML, Gillory LA, Stewart JE, Nabers HC, Mroczek-Musulman E, Waters AM, Coleman JM, Kelly V, Markert JM, **Gillespie GY**, Friedman GK., Beierle EA [Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.](#) PLoS One. 2014 Jan 30;9(1):e86843. doi: 10.1371/journal.pone.0086843. eCollection 2014 Jan 3. PMID: 24497984; PMCID: PMC3907427
190. Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, Fiveash JB, **Gillespie GY**. [A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses.](#) Mol Ther. 2014 Feb 27. doi: 10.1038/mt.2014.22. [Epub ahead of print] PMID: 24572293
191. Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers NW, Grimes SD, Carroll SL, **Gillespie GY**, Whitley RJ, Markert JM. [Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration to Aotus Nonhuman Primates.](#) Hum Gene Ther Clin Dev. 2014 Mar;25(1):16-27. doi: 10.1089/humc.2013.201. PMID: 24649838
192. Han X, Li R, Zhang W, Yang X, Wheeler CG, Friedman GK, Province P, Ding Q, You Z, Fathallah-Shaykh HM, **Gillespie GY**, Zhao X, King PH, Nabors LB. [Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.](#) J Neurooncol. 2014 Mar 25. [Epub ahead of print] PMID: 24664369
193. Han X, Zhang W, Yang X, Wheeler CG, Langford CP, Wu L, Filippova N, Friedman GK, Ding Q, Fathallah-Shaykh HM, **Gillespie GY**, Nabors LB. [The role of Src family kinases in growth and migration of glioma stem cells.](#) Int J Oncol. 2014 Jul;45(1):302-10. doi: 10.3892/ijo.2014.2432. Epub 2014 May 9. PMID: 24819299 PMCID: PMC4079155
194. Smith TT, Roth JC, Friedman GK, **Gillespie GY**. [Oncolytic viral therapy: targeting cancer stem cells.](#) Oncolytic Virother. 2014 Feb;2014(3):21-33. PMID: 24834430 PMCID: PMC4018757
195. Jackson JD, McMorris AM, Roth JC, Coleman JM, Whitley RJ, **Gillespie GY**, Carroll SL, Markert JM, Cassady KA. [Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.](#) Gene Ther. 21(11):984-90. doi: 10.1038/gt.2014.72. PMID: 25119379
196. Anderson JC, Duarte CW, Welaya K, Rohrbach TD, Bredel M, Yang ES, Choradia NV, Thottassery JV, **Gillespie GY**, Bonner J A, Willey CD [Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.](#) Radiother Oncol (2014) 111(3):468-74. doi: 10.1016/j.radonc.2014.04.010. Epub 2014 May 8. PMID: 24813092
197. Friedman GK, Nan L, Haas MC, Kelly VM, Moore BP, Langford CP, Xu H, Han X, Beierle EA, Markert JM, Cassady KA, **Gillespie GY**. [γ134.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.](#) Gene Ther. 2014 Nov 27. doi: 10.1038/gt.2014.107. [Epub ahead of print] PMID: 25427614
198. Lobo MR, Wang X, **Gillespie GY**, Woltjer RL, Pike MM. [Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic](#)

- [vacuole accumulation](#). PLoS One. 2014 Dec 9;9(12):e114110. doi: 10.1371/journal.pone.0114110. PMID: 25490024 PMCID: PMC4260788
199. Oliva CR, Markert T, **Gillespie GY**, Griguer CE. [Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas](#). Oncotarget. 2015 Feb 28;6(6):4330-44. PMID: 25726526 PMCID: PMC4414193
200. Friedman GK, Nan L, Haas MC, Kelly VM, Moore BP, Langford CP, Xu H, Han X, Beierle EA, Markert JM, Cassady KA, **Gillespie GY**. [γ134.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia](#). Gene Ther. 2015 Apr;22(4):356. doi: 10.1038/gt.2015.5. PMID: 25832732
201. Beck BH, Kim H, O'Brien R, Jadus MR, **Gillespie GY**, Cloud GA, Hoa NT, Langford CP, Lopez RD, Harkins LE, Lamb LS Jr. [Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma](#). PLoS One. 2015 May 8;10(5):e0122387. doi: 10.1371/journal.pone.0122387. PMID: 25955158. PMCID: PMC4425513.
202. Warram JM, de Boer E, Korb M, Hartman Y, Kovar J, Markert JM, **Gillespie GY**, Rosenthal EL. [Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW](#). Br. J Neurosurg. 2015 Dec;29(6):850-8. doi: 10.3109/02688697.2015.1056090. PMID: 26073144
203. Tilson SG, Haley EM, Triantafillu UL, Dozier DA, Langford CP, **Gillespie GY**, Kim Y. [ROCK Inhibition Facilitates In Vitro Expansion of Glioblastoma Stem-Like Cells](#). PLoS One. 2015 Jul 13;10(7):e0132823. doi: 10.1371/journal.pone.0132823. eCollection 2015. PMID: 26167936
204. Friedman GK, Moore BP, Nan L, Kelly VM, Etminan T, Langford CP, Xu H, Han X, Markert JM, Beierle EA, **Gillespie GY**. [Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses](#). Neuro Oncol. 2016 Feb;18(2):227-35. doi: 10.1093/neuonc/nov123. PMID: 26188016
205. Willey CD, Gilbert AN, Anderson JC, **Gillespie GY**. [Patient-Derived Xenografts as a Model System for Radiation Research](#). Semin Radiat Oncol. 2015 Oct;25(4):273-80. doi: 10.1016/j.semradonc.2015.05.008. PMID: 26384275
206. Cripe TP, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Markert JM, Waters AM, **Gillespie GY**, Beierle EA, Friedman GK. [Pediatric cancer gene viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children](#). Mol Ther Oncolytics. 2015;2. pii: 15015. Epub 2015 Sep 16. PMID: 26436135
207. Friedman GK, Beierle EA, **Gillespie GY**, Markert JM, Waters AM, Chen CY, Denton NL, Haworth KB, Hutzen B, Leddon JL, Streby KA, Wang PY, Cripe TP. [Pediatric cancer gene viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children](#). Mol Ther Oncolytics. 2015;2. pii: 15016. Epub 2015 Sep 16. PMID: 26436134
208. Lobo MR, Kukino A, Tran H, Schabel MC, Springer CS, Jr., **Gillespie GY**, Grafe MR, Woltjer RL, Pike MM. [Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma](#) PLoS One Dec 8;10(12):e0144488. doi: 10.1371/journal.pone.0144488, 2015.
209. Dobbins GC, Ugai H, Curiel DT, **Gillespie GY**. [A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents](#). PLoS One. 2015 Dec 21;10(12):e0145272. doi: 10.1371/journal.pone.0145272. PMID: 26689910

210. Anderson JC, Taylor RB, Fiveash JB, de Wijn R, **Gillespie GY**, Willey CD. [KINOMIC ALTERATIONS IN ATYPICAL MENINGIOMA](#). *Med Res Arch*. 2015 Jul;2015(3). doi: 10.18103/mra.v0i3.104. PMID: 27158663
211. Patel DM, Foreman PM, Nabors LB, Riley KO, **Gillespie GY**, Markert JM. [Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma](#). *Hum Gene Ther Clin Dev*. 2016 Jun;27(2):69-78. doi: 10.1089/humc.2016.031. PMID: 27314913
212. Gilbert, A. N., Shevin, R. S., Anderson, J. C., Langford, C. P., Eustace, N., Gillespie, G. Y., Singh, R., Willey, C.D. [Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing](#). *J. Vis. Exp.* (112), e54026, doi:10.3791/54026 (2016).
213. Graham CD, Kaza N, Klocke BJ, **Gillespie GY**, Shevde LA, Carroll SL, Roth KA. [Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma](#). *J Neuropathol Exp Neurol*. 2016 Oct;75(10):946-954. PMID: 27516117
214. Bauer D, Pereboeva L, Gillespie GY, Cloud G, Elzaafarany O, Langford C, Markert JM, Lamb LS. [Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma](#). *J. Immunol. Res.* vol. 2016, Article ID 2568125, 10 pages, 2016. doi:10.1155/2016/2568125
215. Waters AM, Stafman LL, Garner EF, Mruthyunjayappa S, Stewart JE, Friedman GK, Coleman JM, Markert JM, **Gillespie GY**, Beierle EA. [Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma](#). *Transl Oncol*. 2016 Oct;9(5):419-430. doi: 10.1016/j.tranon.2016.07.008. PMID: 27751346
216. Thomas ED, Meza-Perez S, Bevis KS, Randall TD, **Gillespie GY**, Langford C, Alvarez RD. [IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice](#). *J Ovarian Res*. 2016 Oct 27;9(1):70. PMID: 27784340
217. Ring EK, Markert JM, **Gillespie GY**, Friedman GK. [Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy](#). *Clin Cancer Res*. 2016 Nov 10. pii: clincanres.1829.2016. [Epub ahead of print] PMID: 27836863
218. Ahluwalia MS, Bou-Anak S, Burgett ME, Sarmey N, Khosla D, Dahiya S, Weil RJ, Bae E, Huang P, McGraw M, Grove LM, Olman MA, Prayson RA, Suh JH, **Gillespie GY**, Barnholtz-Sloan J, Nowacki AS, Barnett GH, Gladson CL. [Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma](#). *J Neurooncol*. 2016 Nov 17. [Epub ahead of print] PMID: 27858267
219. Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, Lu M, Chan TS, Picard D, de Antonellis P, Khuong-Quang DA, Planello AC, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo DM, Dzamba M, Barszczyk M, Medina T, Riemenschneider AN, Morrissy AS, Ra YS, Ramaswamy V, Remke M, Dunham CP, Yip S, Ng HK, Lu JQ, Mehta V, Albrecht S, Pimentel J, Chan JA, Somers GR, Faria CC, Roque L, Fouladi M, Hoffman LM, Moore AS, Wang Y, Choi SA, Hansford JR, Catchpoole D, Birks DK, Foreman NK, Strother D, Klekner A, Bognár L, Garami M, Hauser P, Hortobágyi T, Wilson B, Hukin J, Carret AS, Van Meter TE, Hwang EI, Gajjar A, Chiou SH, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheinemann K, Fleming AJ, Johnston DL, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay DA, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy RG, Lulla RR, Fangusaro JR, Druker H, Bartels U, Grant R, Malkin D, McGlade CJ, Nicolaidis T, Tihan T, Phillips J, Majewski J, Montpetit A,

- Bourque G, Bader GD, Reddy AT, **Gillespie GY**, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Schüller U, Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A. [Integrated \(epi\)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.](#) *Cancer Cell.* 2016 Dec 12;30(6):891-908. doi: 10.1016/j.ccell.2016.11.003. PMID: 27960086
220. Masilamani AP, Ferrarese R, Kling E, Thudi NK, Kim H, Scholtens DM, Dai F, Hadler M, Unterkircher T, Platania L, Weyerbrock A, Prinz M, **Gillespie GY**, Harsh Iv GR, Bredel M, Carro MS. [KLF6 depletion promotes NF-κB signaling in glioblastoma.](#) *Oncogene.* 2017 Feb 6. doi: 10.1038/onc.2016.507. PMID: 28166199
221. Waters AM, Johnston JM, Reddy AT, Fiveash J, Madan-Swain A, Kachurak K, Bag AK, **Gillespie GY**, Markert JM, Friedman GK. [Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.](#) *Hum Gene Ther Clin Dev.* 2017 Mar;28(1):7-16. doi: 10.1089/humc.2017.002. PMID: 28319448
222. Cassady KA, Bauer D, Roth J, Chambers MR, Shoeb T, Clements JC, Prichard M, **Gillespie GY**, Markert JM. [Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.](#) *Molecular Therapy - Oncolytics* 2017 Mar 1;5:1-10. doi: 10.1016/j.omto.2017.02.001. PMID: 28345027
223. Friedman GK, Markert JM, **Gillespie GY**. [Combination strategies enhance oncolytic virotherapy.](#) *Oncotarget.* 2017 May 6. doi: 10.18632/oncotarget.17643. PMID: 28487503
224. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, **Gillespie GY**, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liao LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD. [Intertumoral Heterogeneity within Medulloblastoma Subgroups.](#) *Cancer Cell.* 2017 Jun 12;31(6):737-754.e6. doi: 10.1016/j.ccell.2017.05.005. PMID: 28609654
225. Ring EK, Li R, Moore BP, Nan L, Kelly VM, Han X, Beierle EA, Markert JM, Leavenworth JW, **Gillespie GY**, Friedman GK. [Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.](#) *Mol Ther Oncolytics.* 2017 Sep 13;7:27-36. doi: 10.1016/j.omto.2017.09.003. eCollection 2017 Dec 15. PMID: 29034313
226. Gilbert AN, Walker K, Tran AN, Boyd NH, **Gillespie GY**, Singh RK, Hjelmeland AB. [Modeling Physiologic Microenvironments in Three-Dimensional Microtumors Maintains Brain Tumor Initiating Cells.](#) *J Cancer Stem Cell Res.* 2017;5. pii: e1004. doi: 10.14343/JCSCR.2017.5e1004. Epub 2017 Jul 13. PMID: 29075651
227. Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, **Gillespie GY**, Markert JM, Cassady KA. [Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes](#)

[simplex virus elicit immune mediated anti glioma effect and antitumor memory](#). *Transl Oncol.* 2017 Dec 4;11(1):86-93. doi: 10.1016/j.tranon.2017.10.005. [Epub ahead of print] PMID: 29216507

#### Editorials:

1. Gillespie, G.Y.: The golden age of mononuclear phagocytes. *Survey of Immunologic Research* **1**: 352-356, 1982.

#### Contributions to Books:

1. Russell, S.W., G.Y. Gillespie, and J.L. Pace: Evidence for mononuclear phagocytes in solid neoplasms and appraisal of their nonspecific cytotoxic capabilities. *Contemporary Topics in Immunobiology* **10**: 143-166, 1980.
2. Wharton, W., E.B. Leof, G.Y. Gillespie, J.J. Wyk, and W.J. Pledger: Control of fibroblastic proliferation by the synergistic action of multiple growth factors. In: *Plasma and cellular modulatory proteins*, D.H. Bing and R.A. Rosenbaum, eds., Center for Blood Research, Inc., Boston, MA, pp. 45-57, 1981.
3. Gillespie, G.Y.: Separation of host cells infiltrating tumors and allografts by velocity sedimentation at unit gravity. In: *Cell separation: Methods and selected applications*, Pretlow, T.G., II, and Pretlow, T., eds., Academic Press, New York, pp. 161-183, 1982.
4. Mahaley, M.S., Jr., and G.Y. Gillespie: Immunologic considerations of patients with brain tumors. In: *Oncology of the Nervous System*, M.D. Walker, ed., Martinus-Nijhoff, Boston, pp. 151-165, 1983.
5. Mahaley, M.S., Jr., and G.Y. Gillespie: Immunotherapy of patients with malignant glioma: Fact, fancy and future. In: *Progress in Experimental Brain Tumor Research*, Wilson, C.B. and M.L. Rosenblum, eds., Karger Publishers, Basel, pp. 118-135, 1983.
6. Van Wyk, J.J., W.E. Russell, L.E. Underwood, M.E. Svoboda, G.Y. Gillespie, W.J. Pledger, Adashi, E.Y., and S.D. Balk: Action of somatomedins on cell growth: Effect of selective neutralization of somatomedin-C (Insulin-like growth factor I) with a monoclonal antibody. In: *Human Growth Hormone*, S. Raiti and R.A. Tolman, eds., Plenum Publishing Corp., pp. 585-599, 1986.
7. Gillespie, G.Y., Estes, J.E., and Pledger, W.J. Macrophage-derived growth factors for mesenchymal cells. In: *Lymphokines*, Mizel, S., ed., Academic Press, New York, Volume **11**, pp. 213-242, 1985.
8. Mahaley, M.S., Jr., and G.Y. Gillespie: Immunotherapy of patients with brain tumors - Current prospective. In: *Biology of Brain Tumor*, M.D. Walker & D.G.T. Thomas, eds., Martinus-Nijhoff, Boston, pp. 483-486, 1986.
9. Gillespie, G.Y. and M.S. Mahaley, Jr.: Biological response modifier therapies for patients with malignant gliomas. In: *Human Brain Tumours*, D.G.T. Thomas, ed., Academic Press, London, 1990, pp. 242-282.
10. Gillespie, G.Y. Cytokines As Modulators of Malignant Glioma Progression. Chapter 12, In: *Cytokines and the CNS: Development, Defense and Disease*, R. Ransohoff and E.N. Benveniste, eds., CRC Press, Boca Raton, 1996.

#### Abstracts:

1. Cruse, J.M., J.T. Forbes, B.R. Shivers, and G.Y. Gillespie: Immunosuppression induced by PHA-M and endotoxin in mice. *American Journal of Pathology* **59**: 98a, 1970.
2. Cruse, J.M., J.T. Forbes, B.R. Shivers, and G.Y. Gillespie: Combined effect of PHA-M and endotoxin on immunologic enhancement in mice. *American Journal of Pathology* **59**: 114a-115a, 1970.
3. Cruse, J.M., J.T. Forbes, G.Y. Gillespie, and R.W. Scales: Role of Fc fragments in immunologic enhancement in mice. *Federation Proceedings* **29**: 625, 1970.
4. Cruse, J.M., J.T. Forbes, G.Y. Gillespie, and G.K. Lewis: Effect of endotoxin tolerance on tumor allograft enhancement in mice. *American Journal of Pathology* **62**: 65a, 1971.
5. Cruse, J.M., J.T. Forbes, G.K. Lewis, and G.Y. Gillespie: Effect of sodium alginate on

- immunologic enhancement in mice. *Federation Proceedings* **30**: 512, 1971.
6. Gillespie, G.Y., J.M. Cruse, and L.V. Crawford: An in vitro study of immunologic enhancement. *Federation Proceedings* **30**: 650, 1971.
  7. Gillespie, G.Y., R.F. Barth, and A. Gobuty: A microcytotoxicity assay of alloimmune reactivity utilizing technetium-99m. *Federation Proceedings* **31**: 615, 1972.
  8. Barth, R.F., and G.Y. Gillespie: In vitro detection of allograft immunity by means of the technetium-99m microcytotoxicity assay. Transplantation Abstracts, Fourth International Congress Transplantation Society, p. 18, 1973.
  9. Gillespie, G.Y., and R.F. Barth: Cyclic variations in allograft immunity detected by the technetium-99m microcytotoxicity assay. *Federation Proceedings* **32**: 877, 1973.
  10. Gillespie, G.Y., R.F. Barth, and A. Gobuty: A method for labeling nucleated mammalian cells with technetium-99m. *Journal of Nuclear Medicine* **14**: 400-401, 1973.
  11. Barth, R.F., G.Y. Gillespie, and W. Rosenau: A radioisotopic microassay for lymphotoxin using technetium-labeled cells. Abstracts of American Society for Microbiology, p. 120, 1973.
  12. Gillespie, G.Y., and R.F. Barth: Lymphocyte mediated cytotoxicity against human melanoma detected by the technetium-99m microassay. *Federation Proceedings* **33**: 806, 1974.
  13. Russell, S.W., G.Y. Gillespie, C.B. Hansen, and C.G. Cochrane: Disaggregation of, and identification of, inflammatory cells in regressing and progressing Moloney sarcomas. National Cancer Institute Immunobiology Conference, 1976.
  14. Gillespie, G.Y., C.B. Hansen, and S.W. Russell: Comparison of cytotoxicity of T lymphocytes recovered from regressing or progressing Moloney sarcomas. *Federation Proceedings* **36**: 1305, 1977.
  15. Gillespie, G.Y., C.B. Hansen, and S.W. Russell: Resurgence of killing in vitro by noncytolytic tumor-draining lymph node cells. *Federation Proceedings* **37**: 1382, 1978.
  16. Gillespie, G.Y.: Modulation of killer T lymphocyte development in vitro by inflammatory peritoneal and intratumoral macrophages. Abstracts, Sixteenth National Meetings of the Reticuloendothelial Society, p. 55a, 1979.
  17. Russell, S.W., G.Y. Gillespie, and J.L. Pace: Comparison of tumor cell killing mediated by activated mouse peritoneal macrophages and those of the continuously cultured macrophage line, RAW 264. Abstracts, Sixteenth National Meetings of the Reticuloendothelial Society, p. 56a, 1979.
  18. Gillespie, G.Y.: Monoclonal antiglioma antibody. Proceedings of the Sandie Altman Conference on New Research Ideas for Glioma Therapy, Academic Press, 1980.
  19. Gillespie, G.Y., W. Wharton, W.J. Pledger: Mitogenic activity elaborated by macrophage-like cell lines act as competence factors for BALB/c-3T3 cells. *Federation Proceedings* **40**: 771, 1981.
  20. Shinonaga, M., and G.Y. Gillespie: Rat anti-rabbit erythrocyte monoclonal: hemagglutinating, hemolytic and ADCC activities. *Federation Proceedings* **41**: 598, 1982.
  21. Estes, J.E., G.Y. Gillespie, and W.J. Pledger: Production and partial purification of a mitogenic factor from serum-free P388D1 (mouse macrophage-like continuous cell line). *Federation Proceedings* **42**: 1833, 1983.
  22. Gillespie, G.Y., and P. Golden: Partial characterization of a monoclonal antibody panel against bovine S-100 protein. *Federation Proceedings* **43**: 2025, 1983.
  23. Van Wyk, J.J., L.E. Underwood, G.Y. Gillespie, M.E. Svoboda, and W.E. Russell: Affinity purification of somatomedin-C and immunoneutralization of its mitogenic effects by a monoclonal antibody. (1983 Meeting, The Endocrine Society).
  24. Austin, K.S., G.Y. Gillespie, S.C. Buessow, and H.S. Earp: TLCK inhibits membrane tyrosine-specific protein kinase activity from T but not B lymphocytes. *Federation Proceedings* **43**: 1468, 1984.
  25. Buessow, S.C., M.S. Mahaley, and G.Y. Gillespie: Interferons (IFN) promote myeloid differentiation and augment cytotoxicity of a human promyelocytic leukemia cell line (HL-60). *Federation Proceedings* **43**: 1986, 1984.
  26. Malouf, N.N., G.Y. Gillespie, J.M. Bynum, P.E. Wilson, and G. Meissner: Monoclonal antibodies to rabbit skeletal muscle "triads." *Federation Proceedings* **43**: 1549, 1984.

27. Gillespie, G.Y., S.C. Buessow, and K.G. Nelson: Interferon-gamma induces myeloid differentiation, Leu-1 and Tac expression and reduction of c-myc mRNA in HL-60 cells. *Federation Proceedings* **44**: 569, 1985.
28. Gandhi, B., G.Y. Gillespie, and J. Pick: Characterization of monoclonal antibodies to Toxoplasma gondii tachyzoites by immunochemical techniques. *Federation Proceedings* **44**: 1334, 1985.
29. Earp, H.S., K.A. Austin, S. Buessow, and Y. Gillespie: Differentiation of HL-60 cells increases membrane tyrosine kinase activity. *Federation Proceedings* **44**: 1424, 1985.
30. Theil, E.C., A.R. McKenzie, and G.Y. Gillespie: Cross-linked protomers of apoferritin: Effect in the assembled molecule on immunoreactivity with monoclonal antibodies and electrophoretic mobility. *Federation Proceedings* **44**: 1621, 1985.
31. Meyer, A.A., G.Y. Gillespie, and J.E. Estes: Fibroblast proliferation produced by unstimulated HL-60 cells. *Journal of Cell Biology* **101**: 241a, 1985.
32. Gillespie, G.Y.: Production and characterization of mouse monoclonal antibodies against S-100 protein. *Journal of Neuroimmunology* **10**: 180, 1985.
33. Siegal, G.P., G.Y. Gillespie, S.C. Loeffel, and F.B. Askin: Cells of diverse origin contain S-100 protein - as determined by immunoreactivity to monoclonal antibodies. *Laboratory Investigation* **52**: 26A, 1985.
34. Gillespie, G.Y., J.C. Jennette, R.R. Tidwell, J.D. Geratz, R.T. Falk: Protease inhibitor amelioration of immune complex mediated necrotizing glomerulonephritis (NGN). American Society Nephrology, 18th Annual Meeting (p.126A), 1985.
35. Walsh, R.C., G.Y. Gillespie, and A. Sancar: Production and characterization of monoclonal antibodies to E. coli photolyase (photoreactivating enzyme). *Federation Proceedings* **45**: 1782, 1986.
36. Siegal, G.P., D. Sawhney, E.W. Miller, G.Y. Gillespie, and R.J. Campbell: 'Neurocuprin' and hepatolenticular degeneration. An immunohistochemical study. *Laboratory Investigation* **54**: 58A, 1986.
37. Meyer, A.A., J. Estes, S. DeSerres, and G.Y. Gillespie: Inhibition of growth factor induced fibroblast proliferation by a product of HL-60 cells. *Journal of Cell Biology*. In press, 1987.
38. Meyer, A., J. Estes, S. DeSerres, and G.Y. Gillespie: Human tumor cell growth is inhibited by a large MW product of HL-60 cells. *Federation Proceedings* **46**: 1511, 1987.
39. Dodd, R.C., M.E. Williams, T.K. Gray, and G.Y. Gillespie: Nonidentity of differentiation-inducing factor and human recombinant tumor necrosis factor. (1987 Meeting, American Society for Bone and Mineral Research.)
40. McKenzie, R.A., G.Y. Gillespie, and E.C. Theil: Posttranslational modification of macrophage ferritin (cross-linked subunit dimers): Subunit-specific changes probed with monoclonal antibodies. *Federation Proceedings* **46**: 2023, 1987.
41. Kuratsu, J., J.E. Estes, M.S. Mahaley and G.Y. Gillespie: Growth factors derived from human glioma cells. *Journal of Neuro-Oncology* **5**: 175, 1987.
42. Stackhouse, D., G.Y. Gillespie and M.S. Mahaley: ASV-induced rat glioma cell lines express OX-8, the suppressor/cytotoxic T cell antigen. *Journal of Neuro-Oncology* **5**: 182, 1987.
43. Barnum, S.R., E.N. Benveniste, G.Y. Gillespie, Y. Ishii and J.E. Volanakis: Complement protein and regulation in human astrocytes. *FASEB Journal* **4**: A1871, 1990.
44. Bethea, J.R., G. Y. Gillespie, I.Y. Chung and E.N. Benveniste: Tumor necrosis factor production and receptor expression by a human malignant glioma cell line, D54-MG. *FASEB Journal* **4**: A1918, 1990.
45. Goldman, C.K. and G.Y. Gillespie: REVC: A rabbit endothelial cell line without substrata or supplement requirements. *Journal of Cellular Biochemistry* **15F**: 239, 1991.
46. Tzeng, J.-J., G.Y. Gillespie, A. Waterman and D.R. Shaw: Characterization of human lymphocytes and immunoglobulin in engrafted *scid* mice. *FASEB Journal* **5**: A1374, 1991.
47. Lyon, E. and G.Y. Gillespie: High molecular weight growth activities produced by the human malignant glioma cell line, D-54MG. *FASEB Journal* **5**: A1610, 1991.
48. Bethea, J.R., I.Y. Chung, G.Y. Gillespie and E.N. Benveniste: Interleukin-1 $\beta$  induces TNF- $\alpha$  mRNA and protein production in a human malignant glioma cell line. *FASEB*

- Journal* **5**: A1779, 1991.
49. Tzeng, J.-J., G.Y. Gillespie, A. Waterman and D.R. Shaw: Trafficking of <sup>111</sup>In/Hoechst double-labeled human leukocytes in scid mice. *Proceedings of the American Association for Cancer Research* **32**: 272, 1991.
  50. Sueyoshi, N., E.J. Dropcho, G.Y. Gillespie: Induction of Transforming Growth Factor- $\alpha$  Gene Transcription in Human Glioma Cells by EGF, TGF- $\alpha$  or Lipopolysaccharide. *Journal of Neuro-Oncology*: In press, 1992.
  51. Tzeng, J.-J., Shaw, D.R., Brezovich, I.A., G.Y. Gillespie: Irradiation to enhance scid mouse engraftment by human lymphocytes. *Proc. Amer. Assn. Cancer Res.* in press, 1992.
  52. Tzeng, J.-J., G.Y. Gillespie, D.R. Shaw: Development of immune anemia in human lymphocyte engrafted scid mice. SCID mouse in agricultural and biological sciences. 1992.
  53. Bethea, J.R., G.Y. Gillespie, S.M. Sparacio, E.N. Benveniste: Interleukin1 $\beta$  induction of tumor necrosis Factor- $\alpha$  gene expression: Involvement of protein kinase C. *FASEB J.* **6**: A1715, 1992.
  53. Goldman, C.K., G.Y. Gillespie: EGF induces vascular endothelial growth factor expression in malignant gliomas. *Proc. Amer. Assn. Cancer Res.* **34**: 76, 1993.
  54. Buchsbaum, D.J., W.C. Hixon, D. Miller, M.B. Khazaeli, C. Rodenburg, S. McLean and G.Y. Gillespie: Enhancement of EGF receptor expression in human malignant glioma cells by tumor necrosis factor- $\alpha$ . *AACR Molecular Approaches to Cancer Immunotherapy Meeting*, Asheville, NC November 7-11, 1993.
  55. Tucker, M.A., E. Lyon, G.Y. Gillespie: Production of a bioactive high molecular weight TGF $\beta$  by malignant glioma cell line, D54MG. *Proc. Amer. Assn. Cancer Res. Workshop*, Aspen, CO, July 2-8, 1993.
  56. Buchsbaum, D.J., W.C. Hixon, M.B. Khazaeli, C. Rodenburg, S. McLean and G.Y. Gillespie: Epidermal growth factor receptor expression is modulated by tumor necrosis factor- $\alpha$  in human glioma cells. *Proc. Amer. Assn. Cancer Res.* **35**: 37, 1994.
  57. Tucker, M.A. and G.Y. Gillespie: Production of a novel bioactive glioma-derived high molecular weight transforming growth factor beta. *Proc. Amer. Assn. Cancer Res.* **35**: 39, 1994.
  58. Zhang, M., Goldman, C., L.J. Goodly, J.C. Tsai, G.Y. Gillespie, M.H. Wang, R.K. Singh and G.P. Siegal: A model system for in vitro angiogenesis using a novel human extracellular matrix. *Proc. Amer. Assn. Cancer Res.* **35**: 185, 1994.
  59. Chambers, M.R., S. Chatterjee, R.J. Whitley, G.Y. Gillespie: HSV R3616 therapy of murine glioma in scid mice. *Pediatr. Neurosurg.* **21**: 162, 1994.
  60. Goldman, C. K., J.-C. Tsai, G.Y. Gillespie: Regulation of vascular endothelial growth factor secretion in brain tumor cells. *Journal of the Alabama Academy of Sciences* **65**: 136, 1994.
  61. Ullrich N., Sontheimer, H.W., Gillespie, G.Y., Human Malignant Glioma Cells Express A Unique, Voltage-Gated Chloride Current, Keystone Workshop, "Ion Channels as Therapeutic Targets, November, 1995.
  61. Raben, D., D.J. Buchsbaum, M.B. Khazaeli, M.E. Rosenfeld, G.Y. Gillespie and D.T. Curiel: Adenoviral mediated transduction of genes coding for surface receptors to improve radioligand tumor localization. *10th Annual Meeting of Society for Biological Therapy*, Williamsburg, VA, November 1-4, 1995.
  62. Raben, D., D.J. Buchsbaum, M.B. Khazaeli, M.E. Rosenfeld, G.Y. Gillespie and D.T. Curiel: Strategies to augment radioimmunotherapy via genetic induction of receptors for radioligand binding. *Cancer Gene Ther.* **2**: 330, 1995.
  63. Bharara, S. Goldman, C.K., Palmer, C., Vitek, J. Gillespie, G.Y.: Vascular endothelial growth factor correlates with cerebral edema in meningiomas. *Proc. Amer. Assoc. Cancer Res.* **37**: 57, 1996.
  64. Soroceanu, L., E.R. Flotte, S.S. Andreansky, B. Roizman, R.J. Whitley and G.Y. Gillespie: Efficacy of genetically engineered HSV-1 viruses in treatment of human malignant gliomas. *FASEB J.* **10(6)**: A1272, 1996.
  65. Raben, D., D.J. Buchsbaum, M.A. Stackhouse, G.Y. Gillespie, M.B. Khazaeli, B.E. Rogers and D.T. Curiel Strategies to augment cancer radiotherapy employing gene

- transfer methods. *Emerging Modalities for Therapy of Brain Tumors*, Tahoe, CA, October 28-31, 1996. [CANCELLED]
66. Clary, C.E., Dergachev, A., Kudryavtsev, A., Mirov, S., Gillespie, G.Y.: Effects of sample preparation on laser raman spectroscopic analysis of neurological tissue. *Ann. Biomed. Engineer.* **24(Suppl 1)**: S40, 1996.
  67. R. Miller, B.E. Rogers, T. Carpenter, J.T. Douglas, G.Y. Gillespie, D.J. Buchsbaum, D.T. Curiel and D. Raben. Improved radiolabeled localization to gliomas through the use of targeted adenoviral vectors. Sixth International Conference on Gene Therapy of Cancer Nov 20-22, 1997.
  68. Miller, C.R., Rogers, B.E., Douglas, J.T., Gillespie, G.Y., Raben, D., Buchsbaum, D.J., Curiel, D.T. EGFR targeted adenoviral mediated gene delivery to human glioblastoma tumors. *Proc. Amer. Assoc. Cancer Res.* **39**: 555, 1998.
  69. Tucker, M.A., Lyon, E., McGraw, P., Gillespie, G.Y. Immunochemical identification and partial characterization of a human malignant glioma-derived high molecular weight form of transforming growth factor type  $\beta$  (HMW-TGF $\beta$ ). *Proc. Amer. Assoc. Cancer Res.* **39**: 405, 1997.
  70. Tucker, M.A., Bharara, S., Gillespie, G.Y. Purification of glioma-derived high molecular weight transforming growth factor  $\beta$  (HMW-TGF $\beta$ ) and evidence of its relatedness to TGF $\beta$ 1. *Proc. Amer. Assoc. Cancer Res.* **39**: 405, 1997.
  71. Chambers M.R., Gillespie, G.Y., Markert, J.M., Raben, D., Brezovich, I.A., Roizman, B., Whitley, R.W. Combined approaches for therapy of experimental intracranial malignant gliomas with genetically engineered herpes simplex viruses. AANS meeting 1998.
  72. Miller, C.R., Buchsbaum, D.J., Carpenter, T. Douglas, J.T., Gillespie, G.Y., Curiel, D.T., Raben, D. Retargeting of adenovirus to the epidermal growth factor receptor results in efficient gene delivery to cultured and primary human glioma cells. *Amer. Soc. Gene Therapy*, 1998.
  73. Bharara S., Gillespie, G.Y., Montgomery, R.I., Spear P.G., Whitley, R.J., Roizman B. Expression of human HVEM on murine glioma cells facilitates HSV infection. . Proceedings, 23<sup>rd</sup> International Herpesvirus Workshop, p. 130, 1- 7 August, 1998, York, U.K.
  74. Hubinette, M.M., Qiang, D., Wieczorek, A.A., Ostrove, J.M., Gillespie, G.Y., Tufaro, F., Horsburgh, B.C. Bacterial artificial chromosomes containing HSV sequences: new vectors for cancer and gene therapy. . Proceedings, 23<sup>rd</sup> International Herpesvirus Workshop, p. 271, 1- 7 August, 1998, York, U.K.
  75. Parker, J.N., Markert, J.M., Gillespie, G.Y., Roizman, B., Whitley, R.J.,. Characterization of genetically engineered herpes simplex viruses expressing murine cytokines interleukin-12 or granulocyte-macrophage colony stimulating factor. Proceedings, 23<sup>rd</sup> International Herpesvirus Workshop, p. 284, 1- 7 August, 1998, York, U.K.
  76. Bharara S., Gillespie, G.Y., Montgomery, R.I., Spear P.G., Whitley, R.J., Roizman B. Expression of human HVEM on murine glioma cells facilitates HSV infection. . Proceedings, 23<sup>rd</sup> International Herpesvirus Workshop, p. 130, 1- 7 August, 1998, York, U.K.
  77. Parker, J.N., Gillespie, G.Y., Love, C.E., Roizman, B., Whitley, R.J., Markert, J.M.. Genetically engineered herpes simplex viruses expressing murine cytokines IL-12 or GM-CSF for glioma therapy. *Neuro-oncology* **1**: S45, 1999 (Proceedings of 3<sup>rd</sup> annual Society for Neuro-oncology meeting, San Francisco, Nov. 12-15, 1998).
  78. Parker, J.N., Markert, J.M., Love, C.E., Gillespie, G.Y., Whitley, R.J., Engineered HSV-1 expressing IL-12 or GM-CSF for experimental murine brain tumor therapy. Proceedings, 24<sup>th</sup> International Herpesvirus Workshop, July 17-23, 1999, Boston, MA
  79. Guffey, M.B., Lockett, W.S., Gillespie, G.Y., Whitley, R.J., Markert, J.M. Genetically engineered HSV-1 expressing bacterial cytosine deaminase for experimental murine brain tumor therapy. Proceedings, 24<sup>th</sup> International Herpesvirus Workshop, July 17-23, 1999, Boston, MA
  80. Markert, J.M., M. Medlock, G. Y. Gillespie, F. Feigenbaum, T. Todo, S. Rabkin, W. Hunter, F. Tufaro, R.L. Martuza. Preliminary report on the use of a genetically engineered HSV-1 in the treatment of malignant glioma in humans. Proceedings, 24<sup>th</sup> International Herpesvirus Workshop, July 17-23, 1999, Boston, MA

81. Markert, J.M., M. Medlock, G. Y. Gillespie, F. Feigenbaum, T. Todo, S. Rabkin, W. Hunter, F. Tufaro, R.L. Martuza. Preliminary report on the use of a genetically engineered HSV-1 in the treatment of malignant glioma in humans. *Neuro-Oncology 1*: S106-S107, 1999. (Proceedings of the 13<sup>th</sup> International Conference on Brain Tumor Research and Therapy, Sapporo, Japan, October 4-6, 1999).
82. Guffey, M.B., Lockett, W.S., Gillespie, G.Y., Whitley, R.J., Markert, J.M. Genetically engineered HSV-1 expressing bacterial cytosine deaminase for experimental murine brain tumor therapy. *Neuro-Oncology 1*: S106-S107, 1999. (Proceedings of the 13<sup>th</sup> International Conference on Brain Tumor Research and Therapy, Sapporo, Japan, October 4-6, 1999).
83. Bharara, S., Gillespie, G.Y., Cocchi, F., Campadelli-Fiume, G., Parker, J.N., Markert, J.M., Whitley, R.J., Roizman, B. Transduced expression of the herpes virus Ig-like Receptor by GL-261 glioma cells facilitates HSV entry. *Neuro-Oncology 1*: S106-S117, 1999. (Proceedings of the 13<sup>th</sup> International Conference on Brain Tumor Research and Therapy, Sapporo, Japan, October 4-6, 1999).
84. Guffey, M.B., Lockett, W.S., Gillespie, G.Y., Whitley, R.J., Markert, J.M. Genetically engineered HSV-1 expressing bacterial cytosine deaminase for experimental murine brain tumor therapy. *Neuro-Oncology 1*: 314, 1999. (Proceedings of the 4<sup>th</sup> annual Society for Neuro-oncology meeting, Scottsdale, Nov. 17-21, 1999).
85. Markert, J.M., M. Medlock, G.Y. Gillespie, F. Feigenbaum, T. Todo, S. Rabkin, W. Hunter, F. Tufaro, R.L. Martuza. Preliminary report on the use of a genetically engineered HSV-1 in the treatment of malignant glioma in humans. *Neuro-Oncology 1*: 324, 1999. (Proceedings of the 4<sup>th</sup> annual Society for Neuro-oncology meeting, Scottsdale, Nov. 17-21, 1999).
86. Parker, J.N., Gillespie, G.Y., Love, C.E., Whitley, R.J., Markert, J.M.. Engineered HSV-1 expressing IL-12 or GM-CSF for experimental murine brain tumor therapy. *Neuro-oncology 1*: 329, 1999 (Proceedings of 4<sup>th</sup> annual Society for Neuro-oncology meeting, Scottsdale, Nov. 17-21, 1999).
87. Nabors, L.B., King, P.H., Gillespie, G.Y. Hur is expressed ubiquitously in primary human brain tumors and can bind to multiple cytokine and growth factor mRNAs. *Proceedings of American Association for Cancer Research 41*: 148-149, 2000.
88. Miller, C.R., Buchsbaum, D.J., Johnson, M.R., Diasio, R.B., Gillespie, G.Y. An adenovirus vector encoding cytosine deaminase sensitizes human gliomas to 5-fluorocytosine in an intracranial *scid* mouse model. *Proceedings of American Association for Cancer Research 41*: 670, 2000.
89. Stackhouse, M.A., Arafat, W.O., Xiang, J., Gillespie, G.Y., Curiel, D.T., Buchsbaum, D.J. Bax-mediated radiosensitization of human glioblastoma multiforme cells. *Proceedings of American Association for Cancer Research 41*: 784, 2000.
90. Miller, C.R., Buchsbaum, D.J., Johnson, M.R., Diasio, R.B., Gillespie, G.Y. Replication-competent and -incompetent adenovirus CD/5-FC therapy in three intracranial *scid* mouse glioma models. *Neuro-Oncology*, 2001.
91. Hecker, T., R.J. Grammer, J. Stewart, Y. Gillespie, C.L. Gladson. Characterization of p125FAK expression and alternative splice forms in normal brain and human astrocytic tumor biopsies.
92. Miller, C.R., Buchsbaum, D.J., Williams, D.J., Kiss, P., Christopher, R. Elgavish, G., Grizzle, W.E. Diasio, R.B., Johnson, M.R., Gillespie, G.Y. Cytosine deaminase/5-fluorocytosine therapy for gastrointestinal (GI) and non-GI malignancies.
93. Debinski, W., Slagle-Webb, B., Achen, M.G., Stacker, S.A., Tulchinsky, E. Gillespie, G.Y., Gibo, D. VEGF-D is an X-linked/AP-1 regulated onco-angiogen in glioblastoma multiforme. *Neuro-Oncol. 3*: 267-268, 2001.
94. Hecker, T.P, Grammer, R., Gillespie, G.Y., Stewart, J., Gladson, C.L. Evidence for FAK signaling in anaplastic astrocytoma biopsy samples. *Neuro-Oncol. 3*: 275, 2001.
95. Markert, J.M., Gober, E.H., Randall, S.H., Parker, J.N., Whitley, R.J., Gillespie, G.Y. Characterization of a murine glioma for immunologic or non-immunologic evaluation of mutant HSV-1 therapy of syngeneic intracranial tumors. *Neuro-Oncol. 3*: 292, 2001.
96. Nabors, L.B., Gillespie, G.Y., Rosenfeld, S.S. Monastrol, a small molecule inhibitor of the mitotic kinesin, EG5, impairs glioma migration. *Neuro-Oncol. 3*: 293, 2001.

97. Miller, C.R., Bharara, S., Chiz, S., Buchsbaum, D.J., Gillespie, G.Y. Cytosine deaminase/5-fluorocytosine gene directed enzyme/prodrug therapy for malignant gliomas. *Neuro-Oncol.* **3**: 292-293, 2001.
98. Parker, J.N., Gober, E.H., Markert, J.M., Whitley, R.J., Randall, S.H., Gillespie, G.Y. In vivo characterization of a recombinant HSV-1 expressing IL-12 for 4C8 glioma therapy in a syngeneic murine model. *Neuro-Oncol.* **3**: 294, 2001.
99. Miller, C.R., Bharara, S., Diasio, R.B., Gillespie, G.Y., Blanquicett, C., Buchsbaum, D.J., Johnson, M. Radiation modulates fluoropyrimidine metabolism in human glioblastoma cells through cytokine-mediated induction of thymidine phosphorylase expression. *Proc. Amer. Assn. Cancer Res.* **42**: in press, 2002.
100. Suarez-Cuervo C, Lopez RD, Gillespie GY, Lamb LS Development of a cGMP approvable process for cellular therapy of malignant brain tumors. *Cytotherapy*; **7 (Suppl 1)**: 133, 2006.
101. Bryant NL, Suarez-Cuervo C, Gillespie GY, Nabors LB, Lamb, LS Development of  $\gamma\delta$  T cells as therapy for glioblastoma multiforme. *Neuro-Oncology* **8**: 426, 2006.

### Awards and Honors

Delta Psi Scholarship: 1963, 1964  
 Sigma Xi, University of Kansas: 1971  
 USPHS, National Cancer Institute, Research Service Award (F22-CA04077): 1974-76  
 National Brain Tumor Society Feldman Founder's Award, October 2017

### Invited Presentations (last 28 years)

Yokahama City University School of Medicine, Department of Neurological Surgery, "Immunotherapy of human malignant gliomas", Yokahama, Japan, October 15, 1987.  
 Kumamoto University Medical School, Department of Neurosurgery, "Immunobiology of human malignant gliomas", Kumamoto, Japan, October 24, 1987.  
 Preuss Foundation Seminar - Monoclonal antibody research of brain tumors, "Monoclonal antibody panel to astrocyte antigen, S-100" La Jolla, CA February 7-8, 1988  
 Ohio State University, Immunology Seminar Series, - "Role of TGF $\beta$  in Progression of human malignant gliomas", Columbus, OH March 13, 1989.  
 Ninth International Conference on Brain Tumor Research and Therapy, "Human malignant glioma cell line production of GDGF-2, a high molecular weight growth factor", Asilomar, CA October 16, 1991.  
 Weatherspoon Distinguished Professor (Surgery Grand Rounds) "Autocrine/paracrine growth factors in malignant glioma progression", University of North Carolina at Chapel Hill, Chapel Hill, NC, November 12, 1992.  
 First Biennial AANS/CNS Conference on Brain Tumors: Growth Control in Central Nervous System Tumors, "Expression of vascular endothelial growth factor is induced in malignant gliomas by epidermal growth factor", April 30, 1993.  
 Ninth Annual Neuroscience Symposium, Medical College of Virginia and Richmond Academy of Medicine, "Multiple Growth factor interactions in malignant glioma growth and progression" Richmond, VA, February 24, 1994.  
 Seventh Canadian Neuro-Oncology meeting, "Genetically engineered herpes simplex viruses for therapy of malignant gliomas" Montreal, Quebec, May 29, 1996.  
 Preuss Foundation Seminar - Vaccine Therapy for Primary Malignant Brain Tumors, "Immunization of brain tumor patients with human glioma cells" La Jolla, CA February 25-27, 1998  
 Preuss Foundation Seminar - Vaccine Therapy for Primary Malignant Brain Tumors, "Gene transfer in gliomas with herpes virus vectors" La Jolla, CA February 25-27, 1998

- Third Biennial AANS/CNS Conference on Brain Tumors, "*Role of angiogenesis in glioma progression*", May 1, 1998.
- New Approaches to Brain Tumor Therapy Satellite Symposium on Angiogenesis and Brain Tumor Therapy, "*Cellular and molecular mechanisms of brain tumor angiogenesis*", May 16<sup>th</sup>, 1998, University of South Florida, Tampa, FL
- Penn State/Hershey Medical Center Cell and Molecular Biology Graduate Program Seminar, "*Recombinant Herpes Viruses as Effective Adjuncts in Anti-Tumor Therapies*", Hershey, PA, November ,1998.
- Mount Sinai Medical Center Seminar, Department of Microbiology, "*Genetically engineered Herpes Simplex Viruses for Brain Tumor Therapy: Oncolytic versus Gene Therapy Vectors*", New York City, NY, March 9, 1999.
- Emory University Medical Center, Winship Cancer Center Elkin Cancer Biology Seminar, "*Genetically engineered herpes simplex viruses as anti-glioma agents*", Atlanta, GA, March 12, 1999.
- New Approaches to Brain Tumor Therapy Consortium; Eight Annual NABTT Lecture, "*A Perspective of Emerging Brain Tumor Therapies: Challenges for the Millennium*", Birmingham, AL, May 5, 1999.
- 13<sup>th</sup> International Conference on Brain Tumor Research and Therapy, Workshop, "*Pros and Cons of Animal Models for Brain Tumors*", Lake Toya, Hokkaido, Japan, October 5, 1999.
- 9<sup>th</sup> International Conference on Immunobiology of Herpesvirus Infections, "*Preliminary Report of A Phase I Trial of Herpes Simplex Virus in Patients With Recurrent Gliomas*", Castelvecchio-Pascoli, Italy, October 9, 1999.
- Ohio State University Immunology Seminar Series, "*Mutant Herpes Viruses as Direct Oncolytic and Gene Transfer Agents for Treatment of malignant Gliomas*", Columbus, OH, March 28, 2000.
- University of California at San Francisco Neuro-oncology: Malignant Gliomas Symposium, - "*Replication Conditional Herpes Simplex Viruses (HSV-1) for Malignant Glioma Therapy*", San Francisco, CA, October 7, 2000.
- University of Alabama at Birmingham Gene Therapy Center Research Forum, - "*Replication Conditional HSV As Oncolytic and Gene Transfer Vectors for Human Brain Tumor Therapy*", Birmingham, AL, November 7, 2000.
- 14<sup>th</sup> International Conference on Brain Tumor Research and Therapy, "*5-Fluorocytosine Pro-drug Therapy in Immunocompromised Mice Bearing Intracranial Human Gliomas Treated Intratumorally With Adenoviruses Expressing Cytosine Deaminase (CD) or CD/Uracil Phosphoribosyl Transferase*", Grove Park Inn, Asheville, North Carolina, May 28, 2001.
- Henry Ford Hospital, Hermelin Brain Tumor Research Center Seminar, "*Emerging Viral Therapies for Malignant Brain Tumors*", Detroit, MI, 12 December 2001.
- Mayo Clinic, "*Coordinated Oncolytic Virus-Adjunctive Therapies for Malignant Gliomas*", Rochester, MN, 13 December 2002.
- 13<sup>th</sup> Annual Scientific Meeting, Society of Black Academic Surgeons, *Gene Therapy for Solid Tumors*, Birmingham, AL 5 April, 2003.
- University of Illinois at Peoria, College of Medicine, Departments of Neurosurgery and Biomedical and Therapeutic Sciences, "*Developing smart weapons against brain tumors: Advances with HSV-1 mutants*", Peoria, IL, 5 March 2004.
- University of Virginia, School of Medicine, Departments of Neurology and Neurosurgery Grand Rounds, "*Genetically Engineered Herpes Simplex Viruses For Malignant Glioma Therapy*", 29 August 2004.

Henry Ford Hospital, Hermelin Brain Tumor Research Center, Prashant and Saloni Fadia Symposium, *"Oncolytic Viral Therapy for Malignant Brain Tumors"*, Detroit, MI, 4 November 2005.

Preuss Foundation Seminar - Oncolytic Virus Therapies for Brain Tumors, *"Combined Oncolytic Virus Therapy and Radiation Therapy"* La Jolla, CA November 7-9, 2005

Aspen Symposium: Brain Tumor Immunotherapy, *"Active Cellular Therapy for Brain Tumors: Lessons from the Past"*, Aspen, CO August 7-9, 2006

UAB Experimental Therapeutics Seminar Series, *Strategies for Oncolytic Virus Therapy of Malignant Brain Tumors*, February 15, 2007

UAB Biomedical Engineering Seminar Series, *Encephalitis to Oncolysis: Engineering Herpes Simplex Viruses to Treat Brain Tumors*, March 7, 2008

UAB Neuro-Oncology Seminar Series, *Integrated 'Omics of Patient-Derived GBM Xenolines Proband Models For Personalized Medicine*, October 23, 2013

Southern Research Institute Cancer Research Seminar Series, *Glioblastoma multiforme Model Building: Patient Derived Xenolines for Drug Development and Mechanism Studies*, March 18, 2014

Molecular and Cellular Pathology Seminar Series, *GBM Patient-Derived Xenolines for Mechanistic and Drug Development Studies*, April 29, 2014

Gibbs Cancer Center & Research Institute Spartanburg Healthcare System: 2nd Annual Space, Cancer and Personalized Medicine Conference, *Using Mouse Avatars To Personalize Cancer Therapy: Exploring Agents from Small Molecules to Oncolytic Viruses*, Spartanburg, SC, May 15, 2014.

Hematology & Oncology Research Seminar Series, *GBM Patient-Derived Xenolines (PDX) as Avatars for (Personalized?) Cancer Therapy*, November 30, 2015.

## Current Grant Support

- USPHS/NIH/NCI U01 CA224151-01 (Chambers, MR; PI) *Canine Immuno Neurotherapeutics* \$1,596,668, 9/30/2017 – 8/31/2022 G.Y. Gillespie, PhD, Co-Investigator.
- Hyundai Hope on Wheels (Friedman, GK; PI) *Enhancement of Immunovirotherapy with IDO Inhibition in Pediatric Medulloblastoma* \$125,000, 12/31/2016 – 12/30/2018 G.Y. Gillespie, PhD, Co-Investigator.
- USPHS/NIH/NCI R21 NS100054 (Griguer, CE; PI) *Paracrine Signaling in Glioma: Bioenergetics Heterogeneity and Chemoresistance*, \$275,000, 09/30/2016- 08/31/2018 G.Y. Gillespie, PhD, Co-Investigator.
- USPHS/NIH/NCI U01 NS093663 (Griguer, CE; Markert, JM: Co-PIs) *Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma*, \$1,190,223, 09/30/2016- 06/30/2017 G.Y. Gillespie, PhD, Co-Investigator.
- USPHS/NIH/NCI 1 R01CA217179-01 (Markert, JM; Gillespie, GY, Co-PIs) *A Phase I Study of M032, a Genetically Engineered HSV Expressing Interleukin-12 in Patients with Recurrent/Progressive Glioblastoma multiforme, Anaplastic Astrocytoma or Gliosarcoma* \$1,933,781, 4/01/2017 - 3/31/2020 G.Y. Gillespie, PhD, Co-Investigator.
- USPHS/NIH/NINDS 1 R01 NS095626-01 *Targeting PRMT5 in Glioma Initiating Cells as a New Therapy for Glioblastoma*. (Han, X, MD, PI) \$218,750, 09/30/2015 - 09/30/2020, G.Y. Gillespie, PhD, Co-Investigator.
- USPHS, NIH, NINDS 5 T32 NS48039 (Benveniste, E.N., Ph.D., PI) *Training Program in Brain Tumor Biology*, \$213,406 (Annual Direct Costs) 07/01/07 – 06/30/17

## Past Grant Support (reverse chronological order; last 20 years)

- USPHS, NIH-SBIR Phase II (NCI) HHSN261201500068C (Singh, Raj K., Ph.D., PI), *New Patient-Derived MicroTumor Culture/Assay System* \$1,971,638, 09/22/2015 – 09/21/2017; Subcontract to UAB: \$421,724, Gillespie, G. Y., PhD (PI)
- USPHS, NIH, NCI P20 CA151129-03, SPORE in Neurological Cancer: *Contemporary Therapeutics for Anaplastic Gliomas* (Gillespie, G.Y. Ph.D., PI); **Program Director**, \$486,345 (TDC), Leader, Core A: \$85,182; Leader, Core B: \$69,401; Leader, Core E: \$53,365; 09/21/11 - 05/31/17
- USPHS, NIH, NCI T32 CA 91078-8 *Research Training Program in Surgical Oncology* (Kirby I. Bland, M.D., PI) \$1,575,380 4/1/02 - 3/31/17.
- USPHS, NIH, NCI P30 CA13148-39 , *Cancer Center Core Support Grant*, Edward E. Partridge, M.D. (PI, **Neuro-Oncology Program Co-Leader** \$1,292,453 (TDC); 04/01/2011-03/31/2022
- USPHS/NIH/NCI 1 R01 CA160821-01A1 (Griguer, C.E., Ph.D., PI), *Cytochrome C Oxidase in Malignant Gliomas*, \$207,500 ((Annual direct costs), 06/01/2012 – 03/31/2017, G.Y. Gillespie, PhD, Co-Investigator
- USPHS, NIH, NCI 1 R01 CA158534-01A1 (Benveniste, E.N., Ph.D., PI) *Targeting the JAK/STAT-3 Pathway Signaling Axis in Glioma*, \$207,500 (annual direct costs), 03/01/12 – 02/28/17, G.Y. Gillespie, PhD, Co-Investigator
- USPHS//NIH/NCI 1 R21 CA185712-A1 (Willey, C.D., M.D., Ph.D. (PI)) *3D-Microtumor GBM Xenoline Proband Modeling of Kinome-Directed Therapy*, \$ 151,362 (1st Year Direct Costs), 04/01/14 - 03/31/16, G.Y. Gillespie, PhD, Co-Investigator
- Norma Livingston Foundation (Gillespie, GY & Randall TD, Co-PIs) *Evaluating Novel Oncolytic Viroimmunotherapeutics and Immune Functioning of the Omentum in Ovarian Cancer*, \$50,000 (annual direct costs), July 1, 2014 - June 30, 2015.

USPHS, NIH, NCI P01-CA71933-15 *Engineered Herpes Simplex Viruses for Treatment of Gliomas*, R.J. Whitley, M.D. (PI), **Co-Director and Core Leader**, \$1,049,934 (TDC); Leader, Core B, \$134,349, 8/1/97 - 6/30/2014.

USPHS, NIH, NCI 1 R01 CA138517-01A2 (Nozell, Susan E., Ph.D., PI) *Characterizing the Role of NF- $\kappa$ B in Promoting Glioma Tumorigenicity*, \$225,000, 07/01/10 – 06/30/15

USPHS, NIH-SBIR Phase I (NCI) HHSN261201300024C (Singh, Raj K., Ph.D., PI), *New Patient-Derived MicroTumor Assay System for Efficient Clinical Drug Screening* \$294,274, 09/20/2013 – 06/19/2014; Subcontract to UAB: Gillespie, G. Y., PhD (PI)

Department of Defense CDMRP W81XWH-10-NFRP-IIRA-NF1001157, (Markert, J.M., MD, PI) *Engineered Herpes Simplex Viruses for Treatment of Malignant Peripheral Nerve Sheath Tumors*, \$988,765 (total direct cost), 03/01/11 – 02/28/15

USPHS, NIH, NCI S08-221ST TO4, SAIC-FREDERICK (Chemical Biology Consortium), (Thottassery J., Ph.D., PI), *Interrogation of Key Genomic Alterations in Glioblastoma Multiforme (GBM) for Identification of Molecular Pathways Critical to GBM Tumorigenesis and Progression*, \$1,018,136 (Total Direct Costs), 07/01/10 – 06/30/12. Subcontract to SRI (Gillespie, G.Y. Ph.D., PI), \$829,731 (total direct costs)

USPHS, NIH, NCI P50-CA 097247-05S4, SPORE in Neurological Cancer: *Molecular Therapy for Malignant Gliomas* (Gillespie, G.Y. Ph.D., PI); **Program Director**, Co-Investigator, Project #4, \$208,393; Leader, Core A: \$141,972; Leader, Core B: \$128,166; Leader, Core D: \$183,714; 08/01/02 - 05/31/11

USPHS, NIH, NCI 1-R21-NS066332-01 Lin, Fang-Tsyr (PI) *Role of TRIP6 in Malignant Glioma Progression* \$149,787 (direct costs, 3/15/09 – 4/20/11

USPHS, NIH, NINDS 1-R21 NS067115-01 (Lamb, Lawrence S., Jr., PI) *Donor Innate Lymphocyte Infusion Product for Immunotherapy of Glioblastoma Multiforme*, \$175,000 (direct costs) 3/01/10 – 2/28/11

Ivy/Translational Genomics Genomics-Based Medicine Consortium, *Chemovulnerability and Genomic Profile of Human Glioma Xenografts* (Gillespie, G.Y., PI) \$110,703 (annual costs) 8/1/08 - 1/31/11

TransMolecular, Inc., TMI-2007-01: Restricted Title (Gillespie, G.Y., PI) \$12,135 6/1/07 - 5/31/10)

USPHS, NIH, NCI P50 CA097247-05S2 *Molecular Therapeutics for Anaplastic Gliomas, Role of the RNA De-stabilizer, TTP, in Regulating STAT-3 and NF- $\kappa$ B Mediated Gene Expression* (Gillespie, G.Y., PI) Research Supplement for Underrepresented Minorities Program, Dr. Esther Suswam. \$89,186 8/01/05 – 5/31/08

Oncolytics Biotech, Inc., Calgary, Canada, *Reovirus Synergy with Radiotherapy and Temozolomide in Experimental Brain Tumor Models* (J. N. Parker, Ph.D., PI) \$335,290, 08/01/06-07/31/08

American Cancer Society (Martin Johnson, Ph.D., PI); *“A Rational Pharmacogenomic Approach for Treating Glioblastoma Multiforme. \$150,000, (Co-Investigator)”* 3/1/04 – 2/29/08.

DOD DAMD17-02-1-0004 (Savafy, A, Ph.D., PI) *Paclitaxel-mono-clonal antibody conjugates for targeted therapy of prostate carcinoma*, \$75,000, (**Co-Investigator**), 11/01/01 – 10/31/05.

USPHS, NIH, NCI P50 CA101955-01-01 (S.M. Vickers, M.D., PI); *Molecular Therapeutics Developing New Targets for Treatment of Pancreatic Cancer: (Principal Investigator) Oncolytic Pro-drug Converting herpesvirus Therapy of Human Pancreatic Cancer*, \$50,000/yr, 7/01/03 - 6/30/08.

SunBioChem Contract (G.Y. Gillespie, Ph.D., **Principal Investigator**); *“Preclinical evaluations of novel therapies of human tumor cells in immunocompromised mice”*; \$20,000, 3/15/2004-3/14/2005.

USPHS, NIH, NCI U19-CA67763-10 *Tumor sensitization to purine analogs by E. Coli PNP*, Parker, W.B., Ph.D. (PI); **Co-Investigator**, Project #1 \$129,594 07/01/95-06/30/2005.

DOD DAMD17-02-1-0268 (Savafy, A, Ph.D., PI) *Paclitaxel-monoclonal Antibody Conjugates for Targeted Chemotherapy of Breast Cancer*, \$97,043, (**Co-Investigator**), 04/01/02 - 03/31/05.

MediGene, Inc. (NeuroVir, Ltd). *In Vivo Assessment of Herpes Simplex Virus - 1 Mutants In Animal Models* G.Y. Gillespie, Ph.D. (**PI**) \$165,735 10/1/99 - ongoing.

The Brain Tumor Society (Parker, J.N., Ph.D., PI), *Immunotherapy of Malignant Gliomas Using Cytokine-expressing  $\Delta\gamma_134.5$  HSV*, \$175,923 (**Co-Investigator**), 09/01/02 – 08/31/04.

PBTFUS (Pediatric Brain Tumor Foundation of the U.S) *Cytosine deaminase-secreting adenovirus for brain tumor therapy*. G.Y. Gillespie, Ph.D.(**PI**) \$70,000, 10/1/00 - 9/30/02.

JCR BioPharmaceuticals, Inc. *In Vivo Assessment of Intracerebral Tumorigenicity of Human Tumor Cells In Immunocompromised Mice* G.Y. Gillespie, Ph.D. (**PI**) \$20,000, 2/1/01 - 1/31/03.

USPHS, NIH, NINDS/NCI P01-NS34856 *Molecular and cellular biology of human gliomas*, **Co-Investigator**, Steven S. Rosenfeld, M.D., Ph.D. (PI) \$736,329 12/01/96 - 11/30/2001

PBTFUS (Pediatric Brain Tumor Foundation of the U.S) *Cytokine expressing recombinant herpes simplex viruses for brain tumor therapy* G.Y. Gillespie, Ph.D.(**PI**) \$35,000, 7/1/97 - 10/30/00.

NeuroVir, Ltd. *In Vivo Assessment of Herpes Simplex Virus - 1 Mutants As Oncolytic Agents In Murine Models of Malignant Disease* G.Y. Gillespie, Ph.D. (**PI**) \$60,206 4/1/97 - 9/30/98.

ACS Institutional Award, Subproject IN-15-S: Regulation of killer T lymphocyte production by intratumoral macrophages; G.Y. Gillespie, Ph.D. (P.I.); \$4,600; 7/1/77 - 6/30/78

Cancer Research Center Starter Grant: Production and partial purification of a macrophage-derived growth factor; G.Y. Gillespie, Ph.D. (P.I.); \$2,000; 3/1/79 - 2/29/80

ACS Institutional Award, Subproject IN-15-W: Production of syngeneic monoclonal antibodies to primary rat brain tumors; G.Y. Gillespie, Ph.D. (P.I.); \$5,000; 7/1/81 - 6/30/82

USPHS, NIH Division of Research Resources S07 FR05406-Subproject: Monoclonal antibodies to glioma cell surface antigens (Medical Faculty Research Award); \$2,000; 6/1/81 - 5/31/82

USPHS, NIH, NCI R01CA30479: Mononuclear phagocyte-derived growth regulating factor(s); G.Y. Gillespie, Ph.D. (P.I.); \$225,492; 8/1/81 - 3/31/85

USPHS, NIH, NCI R01CA29125: Monoclonal antibodies to glioma cell surface antigens; G.Y. Gillespie, Ph.D. (P.I.); \$168,585; 4/1/82 - 3/31/85

North Carolina Biotechnology Center, Monoclonal Lymphocyte Technology Center, MLTC-01: Optimization of Production of Human-Human Hybridomas, G.J. Smith, Ph.D. and G.Y. Gillespie, Ph.D., (Co-P.I.s); \$166,264; 12/1/84 - 11/30/86

USPHS, NIH, NCI R01CA30479: Mononuclear phagocyte-derived growth factor(s); G.Y. Gillespie, Ph.D. (P.I.); \$262,739; 4/1/85 - 3/31/89

USPHS, NIH, NCI R01CA29125: Monoclonal antibodies to gliomas; G.Y. Gillespie, Ph.D. (P.I.); \$177,549; 4/1/85 - 5/31/88

North Carolina Biotechnology Center, #85-G-01003: Immunological identification of the src Oncogene Product and unique surface antigens in virally-induced gliomas, P.F. Maness, Ph.D., and G.Y. Gillespie, Ph.D. (Co-P.I.s); \$3,000; 5/1/85 - 10/31/86

Preuss Foundation, "Human monoclonal antibodies to glioma antigens", G.Y. Gillespie, Ph.D. (PI); \$37,480 annual direct costs, 1/1/88-12/31/89.

USPHS, NIH, NCI R01CA51857: Human Tumor-specific Antibodies Produced in SCID Mice, D.R. Shaw, Ph.D. and G.Y. Gillespie, Ph.D. (Co-P.I.s); \$289,260; 5/1/90 - 4/30/93

American Brain Tumor Association: Angiogenesis Mechanisms of Malignant Brain Tumors, Corey K. Goldman, M.D., Fellow; G. Y. Gillespie, Ph.D. (Sponsor); \$50,000, 07/01/91 - 06/30/93

USPHS, NIH, NCI F31 CA60350: Human Glioma-derived High Molecular Weight TGF $\beta$ , Mary A. Tucker, Pre-doctoral Fellow; G.Y. Gillespie, Ph.D., Sponsor; \$29,370 10/01/92 - 12/31/94

American Medical Association Education & Research Foundation : *"Regulation of Vascular Endothelial Growth Factor in Tumor Angiogenesis"* G.Y. Gillespie, Ph.D. (PI); 06/01/93 - 12/31/94; \$19,500

National Alopecia Areata Foundation: *"Role and Potential Therapeutic Use of Vascular Endothelial Growth Factor in Alopecia Areata"*; G.Y. Gillespie, Ph.D. (PI); 09/01/93 - 11/30/94; \$10,000

Milheim Foundation: *"Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis"*; G.Y. Gillespie, Ph.D. (PI); 07/01/93 - 12/31/94; \$8,510

USPHS, NIH, NINDS; 5-T32-NS07335: Molecular Neuroimmunology and Neuroimmunomodulation, John N. Whitaker, M.D. (P.I.), G. Yancey Gillespie, Ph.D. (Preceptor); \$562,654; 07/01/90 - 06/30/95

USPHS, NIH, NINDS P20 NS31096: Molecular and Cellular Biology of Human Glial Tumors (E.J. Dropcho, M.D., Program Director); Project #2 - Role of Transforming Growth Factor- $\beta$  (TGF $\beta$ ) in Glioma Progression, G. Y. Gillespie, Ph.D. (Co-Program Director and Project #2 Leader); \$746,893 (Program); \$128,376 (Project #2); 09/30/92 - 9/29/95

Novapharm Biotech: *"Tissue antigen distribution, tumor localization and potential therapeutic efficacy of human anti-glioma monoclonal antibody BT32/A6"*; G. Yancey Gillespie, Ph.D. (PI); 04/01/94 - 03/31/96; \$57,042

Department of Energy DE-FG05-93ER61654: "Radiopharmaceutical and Gene Therapy Program" D.J. Buchsbaum, Ph.D. (PI); Project #1 - "Amplification of Epidermal Growth Factor Receptor on Gliomas to Increase Binding of Radiopharmaceuticals"; G. Yancey Gillespie, Ph.D. (Project Leader on Project #1); \$899,001 (Program); \$329,354 (Project #1); 08/01/93 - 01/31/97.

